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BRCA1 and 53BP1 Mediate Reprogramming Through 
DNA Repair Pathway Choice 
Daniela Georgieva 
BRCA1 is a caretaker of genome integrity with various molecular functions, which are 
required for development and tumor suppression. These include the homology-directed repair 
(HDR) of DNA double strand breaks, stalled replication fork protection (SFP), transcription, 
chromatin remodeling and cell cycle checkpoint control. Recent studies reported that BRCA1 is 
required for reprogramming to pluripotency, but its specific role remains unknown. In this work, 
we use separation of function mutants for the roles of BRCA1 in HDR and SFP to show that 
BRCA1 is required to repair replication-associated DNA double strand breaks by homologous 
recombination during reprogramming. Deficiency in SFP proved inconsequential to induced 
pluripotent stem (iPS) cell generation and cells with this phenotype did not experience reduced 
reprogramming. Thus, the primary limiting factor for the transition to pluripotency is a specific 
class of DNA damage: double strand breaks, likely occurring in late replicating regions which 
require repair by homologous recombination.  
These findings identify an important role of DNA damage, linked to the progression of 
DNA replication, in limiting cell type transitions during reprogramming. Most studies on iPS cell 
generation have focused on gene expression as a limiting step, in part due to the wide availability 
of tools to analyze transcription. Since the progression of DNA replication and DNA damage 
during S-phase are cell type specific, we have started the development of a sequencing platform 
to map various aspects of replication progression, such as origin usage, polymerase direction, 
  
 
pausing and stalling. In this work, we demonstrate that nucleotide analogs, incorporated during 
DNA synthesis in mammalian cells, can be detected by Nanopore sequencing. 
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CHAPTER 1: INTRODUCTION 
1.1.THE TUMOR SUPPRESSOR BRCA1 
BRCA1 is a tumor suppressor with multiple molecular functions, which play important 
roles in the maintenance of genome stability. Germline mutations in BRCA1 significantly increase 
the risk of breast and ovarian cancer [1] and are associated with higher incidence of fallopian tube, 
prostate, stomach and other malignancies, reviewed in Roy et al. [2]. Pathogenic mutations have 
been described in all domains of the protein, but most are truncations which eliminate or severely 
affect the BRCT domains [3, 4]. Two common BRCA1 alterations are the Ashkenazi founder 
mutations 185AGdel and 5382insC, both of which are frameshifts leading to a truncated protein 
[4]. While 5382insC is prevalent in European countries, 185AGdel has been found in patients of 
European, American, African and Asian descent [5]. The cumulative lifetime risk of developing 
breast cancer for BRCA1 mutation carriers is 70-80% [2]. BRCA1-asscoicated breast cancers are 
typically triple negative (ER-negative, PR-negative, HER2-negative) and highly aggressive [6]. 
The tissue tropism of BRCA1 tumors has not been formally explained, but an attractive possibility 
is accelerated loss of heterozygosity (LOH) in mammary tissue due to increased rates of mitotic 
recombination [7]. The landmark cloning of BRCA1 in 1994 [1] provided the opportunity to 
discover, characterize and establish ways to manipulate the mechanisms of BRCA1-dependent 
tumor suppression with therapeutic intent. 
1.2. BRCA1 PROTEIN DOMAIN ORGANIZATION  
BRCA1 (Breast Cancer Associated 1 Early Onset) is an 1863 amino acid protein, which 
maps to the long arm of human chromosome 17 [8]. BRCA1 participates in multiple molecular 
pathways with important consequences for genomic stability and cell proliferation. Complete loss 
of BRCA1 is embryonic lethal, which required the generation of hypomorphic alleles and tissue 
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specific knockouts to model the disease in mice [9]. The main functional units of the BRCA1 gene 
product are an N-terminal RING-finger domain, a DNA-binding domain, a serine cluster, and two 
copies of C-terminal BRCT repeats [10]. (Fig.1). The RING-finger is required for the formation 
of the BRCA1-BARD1 heterodimer which enhances the E3 ligase activity of BRCA1, but is not 
needed for tumor suppression [11]. The region between Exon11 and Exon13 spans over half of the 
BRCA1 protein and provides surface for interaction with RB1 (RB transcriptional corepressor 1), 
the bHLH transcription factor cMYC, the double strand break repair protein RAD50, PALB2 
(Partner and Localizer of BRCA2) and the RAD51 recombinase, which are involved in cell cycle 
control and DNA repair [12]. The serine cluster domain between aa1280 and aa1524 contains 
serine residues which are phosphorylated by ATM/ATR kinases in response to DNA damage and 
have been linked to ionizing irradiation induced S-phase (S1387) and G2/M (S1423 and S1524) 
cell cycle arrest [13, 14]. Another important phosphorylation site is the CHK2 target S988, which 
has been shown to regulate homologous recombination [15]. The C-terminal of BRCA1 provides 
a phosphoprotein binding surface for ABRAXAS/CCDC98, the DEAH family helicase 
BACH1/BRIP1 (BRCA1-Intercating Protein C-terminal helicase 1) and CTIP/RBBP8 (RB-
Binding Protein 8 endonuclease), which form mutually exclusive complexes with BRCA1 at 
S1655 (S1598 in mouse Brca1) [16] and play roles in DNA repair and checkpoint control [17-19]. 
The C-terminal of BRCA1 can also associate with EP300 (E1A binding protein p300), which is 
involved in transcription [20]. Most of the identified cancer-predisposing BRCA1 lesions generate 
a truncated protein, missing one or both BRCT domains [3], which underscores their importance 








Figure 1. Schematic of human BRCA1 protein.  
The RING (Really Interesting New Gene) domain of BRCA1 from aa10 to aa109 is followed by 
a DNA Binding Domain (aa452-1092) and a Serine Cluster (SQ) domain (aa1280-1524). Two 
pairs of BRCT repeats span the regions aa1640-1729 and aa1760-1821. The binding sites of 
several BRCA1-interacting partners are marked in blue. Many of the interacting factors are 
implicated in somatic cell reprogramming, including Rb [21], cMyc [22], Rad51 [23], Brca2 [24] 
and CtIP [25]. Selected ATM/ATR targets are shown in the serine cluster domain. The interaction 











1.3. MOLECULAR FUNCTIONS OF BRCA1 
BRCA1 is a member of various protein complexes with important molecular functions. In 
addition to its critical role in DNA double strand break repair by homologous recombination (HR), 
BRCA1 is involved in stalled replication fork protection (SF), chromatin remodeling, transcription 
and cell cycle checkpoint control [26] (Fig. 2).  
 
 
Figure 2. Molecular functions of BRCA1. 
The tumor suppressor BRCA1 has important roles in various molecular processes. BRCA1 
functions in DNA double strand break repair by homologous recombination (HR), stalled 










1.3.1. REPAIR OF DOUBLE STRAND BREAKS BY HOMOLOGOUS RECOMBINATION  
A key molecular role of BRCA1 is in the repair of DNA double strand breaks (DSBs) by 
homologous recombination (HR) [27]. Such lesions occur in response to ionizing irradiation, 
treatment with alkylating or crosslinking agents, oxidative damage related to cell metabolism and 
problems during DNA replication [28]. Single strand breaks (SSBs), for example, are converted 
to DSBs during replication when the replisome runs through the affected region [29]. Stalled 
replication forks can also cause DSBs if they collapse or are degraded by nucleases [30]. Single 
ended DSBs, such as the ones generated by fork cleavage or collapse, are preferentially processed 
by HR as the competing non-homologous end joining (NHEJ) pathway can lead to lethal 
translocations [31]. Homologous recombination is a mostly error-free DSB repair pathway, which 
relies on homology to a sister chromatid. Thus, while NHEJ is active throughout the cell cycle, 
HR is only available in S and G2. An important function of BRCA1 in HR is to inhibit 53BP1, a 
main factor in NHEJ, and thus direct the repair pathway choice to HR [32]. The frequency of HR 
is greatly reduced in BRCA1 deficient cells, which leads to genomic instability with 
developmental consequences [33] and increased cancer susceptibility [34]. Inactivation of 53bp1 
in Brca1 mutant cells rescues their HR deficiency by eliminating the competition for DSB repair 
with 53bp1 [35]. The coiled coil domain of BRCA1 contains a PALB2 binding site which is 
required for the interaction with BRCA2 [36] and the formation of RAD51 filaments in the late 
steps of HR.  
1.3.2. PROTECTION OF STALLED REPLICATION FORKS  
Replication fork stalling occurs at sites of DNA lesions, in regions with difficult to replicate 
repetitive sequences [37], due to collisions with transcription complexes [38], or as a result of 
replication stress in the presence of activated oncogenes [39]. One pathway to resolve stalled 
replication is by fork regression, catalyzed by the SNF-2 family translocase SMARCAL1 [40]. 
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This process involves annealing of the two nascent strands to each other, which generates an 
intermediate structure, termed “chicken foot” [41]. Stalled forks, resolved via “chicken foot”, 
require protection by BRCA1, BRCA2 and RAD51 from MRE11-dependent nucleolytic 
degradation [42, 43] (Fig. 3). Depleting SMARCAL1 rescues the stalled fork protection (SF) 
deficiency of BRCA1 mutant cells and reduces the levels of genome instability [42].  
 
 
Figure 3. Role of BRCA1 in stalled replication fork protection (SFP).  
The SMARCAL1 translocase is recruited to stalled replication forks in an RPA-dependent manner 
[40]. Fork reversal by SMARCAL1 generates a “chicken foot” intermediate. This structure is 











A role of BRCA1 in transcription has been suggested by its association with core 
components of the transcription machinery, such as RNA Pol II and RNA helicase A [44, 45]. In 
addition, BRCA1 has been reported to interact directly with the transcriptional co-activator P300 
[20]. These findings are thought to reflect the role of BRCA1 in transcription-coupled repair, rather 
than promoter activation since BRCA1 binds to RNA Pol II post transcription initiation [46]. 
BRCA1 also modulates the activities of several transcription factors, which control proliferation, 
cell cycle arrest and apoptosis. For example, the N-terminal of BRCA1 binds to ER-α to quench 
ER-α-dependent transcription, which might have implications in tumor suppression [47]. 
Similarly, BRCA1 inhibits the transcriptional activities of another oncogene-cMYC [48]. Besides 
curbing the transformative potential of oncogenes, BRCA1 has been shown to interact with tumor 
suppressors, such as TP53 (Tumor Protein 53). Binding of BRCA1 to TP53 stimulates the 
induction of TP53 target genes, including P21/CDKN1A, which induces cell cycle arrest [49].  
1.3.4. CHROMATIN REMODELING 
The BRCT domains of BRCA1 associate with components of the histone deacetylase 
complex-HDAC1 and HDAC2 [50]. BRCA1 can also directly interact with BRG1, which is a 
component of the SWI/SNF complex [51]. Furthermore, BRCA1 has been reported in a complex 
with BACH1/BRIP1, a DEAH family helicase [52], which plays a role in the DNA damage 
response [18]. The activities of BRCA1 in chromatin remodeling are likely related to DNA repair, 
recombination and transcription which require changes in chromatin state [12].  
1.3.5. CELL CYCLE CHECKPOINT CONTROL  
The Serine Cluster domain of BRCA1 between aa1280 and aa1524 contains several serine 
residues, phosphorylated by ataxia telangiectasia mutated (ATM) and RAD3-related (ATR) 
kinases in response to DNA damage and implicated in cell cycle checkpoint control. These include 
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S1387 [13], required for the S-phase checkpoint, as well as, S1423 and S1524 for the G2/M 
checkpoint [14, 53]. Furthermore, BRCA1 regulates the expression of CHK1, which has a role in 
the induction of G2/M arrest [54]. In response to DNA damage, BRCA1 is phosphorylated at S988 
by CHK2, which is also involved in the G2 to M transition. Mouse models lacking the Chk2 
phosphorylation site have reduced ability to activate the G2/M checkpoint and are tumor prone 
[55].  
1.4. THE BRCA1-INTERACTING PARTNER BARD1 
BRCA1 in vivo exists in a heterodimeric complex with BARD1 (Brca1 Associated RING 
Domain 1)- a 777 amino acid protein with an N-terminal RING motif, three ankyrin repeats and 
two sets of C-terminal BRCT repeats [56] (Fig.4). BARD1 interacts with BRCA1 through helices 
in the vicinity of its RING motif [56] and this association is important for BRCA1 stabilization 
[57] and recruitment to sites of DNA damage [58]. Loss of either BARD1 [59] or BRCA1 [9] is 
embryonic lethal, which shows that the BARD1/BRCA1 heterodimer mediates the role of BRCA1 
in development. Mammary-specific ablation of BARD1 leads to the development of breast 
carcinomas in mice, similar to BRCA1 inactivation [60]. Germline mutations in BARD1 have been 
described in hereditary breast and ovarian cancer patients [61], which underscores the importance 
of the BARD1/BRCA1 interaction for tumor suppression. Two residues in the BRCT domain of 
BARD1, S575 (S563 in mouse Bard1) and K619 (K607 in mouse Bard1), have been shown to play 
a role in PARP-mediated recruitment of BRCA1 to stalled replication forks [62]. Disrupting S563 
or K607 renders cells unable to protect stalled replication forks from degradation without 








Figure 4. Schematic of human BARD1 protein. 
The protein product of BARD1 contains an N-terminal RING-domain, three tandem ankyrin 
repeats and two copies of a C-terminal BRCT motif. The residues, which play a role in stalled 



























1.5. MARKERS OF REPLICATION STRESS AND DNA DAMAGE 
 The presence of RPA (Replication Protein A) nuclear foci in cycling cells is a physiological 
phenomenon, related to the progression of DNA replication. The number of RPA foci increases in 
in the context of replication stress, induced by treatment with hydroxyurea or the cross-linking 
agent mitomycin C (MMC) [63] due to accumulation of excessive amounts of ssDNA from stalled 
replication forks. The p32 subunit of RPA is phosphorylated by ATR at S33 in response to 
replication stress in late S and G2 phases of the cell cycle [64]. The phosphorylation of RPA plays 
a role in the recruitment of PALB2 to stalled replication forks and subsequent fork recovery [65].  
 The phosphorylated form of histone variant H2AX at S139, termed γ-H2AX is a widely 
accepted marker of DNA double strand breaks (DSBs). Phosphorylation in response to DNA 
damage is carried out by ATM [66], while phosphorylation at sites of stalled replication forks is 
mediated by ATR [67]. Phosphorylated H2AX can accumulate over a region as large as 2MB 
surrounding the lesion [68] and plays a role in the recruitment of DNA repair proteins, such as 
NBS1 and BRCA1 [69].  
1.6. REPAIR OF DNA DOUBLE STRAND BREAKS 
Homologous recombination (HR) and non-homologous end joining (NHEJ) are the 
primary pathways for the repair of DNA double strands breaks (DSB) in cells (Fig.5). Homologous 
recombination is active in S and G2, while NHEJ is available throughout the cell cycle [70]. Repair 
by HR is mostly error free and depends on the presence of a sister chromatid. It is a slow process, 
estimated to require as long as 7 hours or more in human cells [71]. The tumor suppressor BRCA1 
has been shown to promote HR in mouse embryonic stem cells [27]. BRCA1 is phosphorylated 
by CHK2 [72] and ATM/ATR [13, 14] kinases, which become active in response to DNA damage. 
Phosphorylated BRCA1 inhibits the activities of 53BP1 in S and G2 phases of the cell cycle and 
drives repair pathway choice to HR [73]. The first step of repair by HR is end resection, initiated 
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by the MRN complex (MRE11/RAD50/NBS1) and stimulated by CTIP [74]. More extensive 
resection is accomplished by EXO1 and BLM/DNA2 [75], generating single stranded DNA, 
coated by RPA. In the next steps of HR, BRCA2 facilitates the displacement of RPA by RAD51 
and the assembly of RAD51 filaments on ssDNA [76, 77], which is a key requirement for 
homology search. In its late stages, HR involves strand invasion, DNA synthesis, ligation and 
holiday junction resolution [78].  
Non-homologous end joining (NHEJ) is a fast (~30min) [71] error prone repair pathway 
active in all cell cycle phases. A main player in NHEJ is 53BP1, which is phosphorylated by ATM 
in response to DNA damage [70]. Active 53BP1 recruits RIF1 and PTIP which inhibit end 
resection [79, 80], thereby directing repair pathway choice to NHEJ. The repair process begins 
with the binding of the KU70/80 heterodimer to the DNA ends which are held together through 
interaction with DNA-PKcs [81]. Removal of overhangs, loops and flaps is accomplished by the 
DNA-PKcs/Artemis complex [82]. Finally, the ends are joined by DNA ligase IV and XRCC4, 
which stabilizes DNA ligase IV and stimulates its activity [83]. Mismatched ends require the 
activity of an additional factor, XLF [84]. Due to its template independence, NHEJ repair is prone 







Figure 5. Main pathways for the repair of DNA double strand breaks (DSBs). 
Two-ended DSBs can be repaired by homologous recombination (HR) or non-homologous end 
joining (NHEJ). While HR is only active in S and G2, NHEJ is available throughout the cell cycle. 
BRCA1 stimulates HR by inhibiting the NHEJ repair factor 53BP1. The first step in HR is end 
resection, followed by RAD51 filament formation. The late stages involve strand invasion, DNA 
synthesis and holiday junction resolution, which concludes the error-free repair of the lesion. 
Alternatively, the ends of the break can be bound by KU70/80 and ligated by LIGIV/XRCC4, 




















1.7. THE NHEJ REPAIR FACTOR 53BP1 
53BP (p-53 Binding Protein 1) is a 1972 amino acid DNA repair factor involved in non-
homologous end joining (NHEJ). NHEJ joins two broken DNA ends, such as in V(D)J and class 
switch recombination (CSR), which occur during immune system development, or after ionizing 
radiation. Mice, deficient in 53BP1 are hypersensitive to IR and prone to lymphomas [85].  The 
N-terminal of 53BP1 has 28 S/T-Q sites, which can be phosphorylated by ATM and other kinases 
[73] (Fig.6). The S/T-Q sites are followed by a Tudor domain and a pair of BRCT repeats at the 
C-terminal of 53BP1 [86]. In DNA double strand break (DSB) repair, 53BP1 acts as scaffold to 
recruit additional NHEJ factors. These include RIF1 (RAP-Interacting Factor 1) and PTIP (Pax 
Transactivation activation domain Interacting Protein), which associate with phosphorylated 
53BP1 [87, 88]. In S and G2 phases of the cell cycle, BRCA1 promotes dephosphorylation of 
53BP1, which directs DSB repair pathway choice to HR [32]. The activity of 53BP1 is highly 
consequential to cell proliferation and survival in the absence of BRCA1. Ablation of 53bp1 in 
Brca1-deficient mice rescues their embryonic lethality [33]. Similarly, loss of 53BP1 in BRCA1 
mammary tumors confers resistance to PARP inhibitors by restoring HR competence [89]. Another 
function of 53BP1 in DNA repair is to amplify ATM signaling in response to DNA damage [90]. 
In the absence of 53BP1, the phosphorylation of ATM targets, is reduced [91]. The relationship 
between 53BP1 and p53 remains to be fully defined, but 53BP1 has been implicated in the 
transcriptional activities of p53 [92]. Loss of 53BP1 was reported to interfere with the induction 
of p21, BAX and other targets in response to DNA damage in cultured human cancer cells [92]. 
Another study, however, showed normal activation and stabilization of p21 in the absence of 






Figure 6. Schematic of human 53BP1 protein. 
The N-terminal of 53BP1 contains 28 Ser/Thr-Gln sites, phosphorylated by ATM and other 
kinases. Phosphorylated sites 1-8 are bound by PTIP, while RIF1 binds to the next 7 sites towards 
the C-terminal [94]. The oligomerization domain (OD) spans the region from aa1231 to aa1277 
and is followed by a Tudor domain (aa1480 to aa1540) and an ubiquitylation-dependent 
recruitment (UDR) motif. Two BRCT repeats, shown in pink, have been mapped to the C-terminal 
of the protein. Sites of interaction between 53BP1 and other factors are marked in blue. The 














1.8. PROCESSING OF STALLED REPLICATION FORKS 
Stalled forks occur during normal conditions in replicating cells, but are accumulated in 
response to replication stress and in the absence of factors required for their stabilization and repair 
[42]. Fork stalling can occur at sites of tightly bound proteins, DNA secondary structures and DNA 
lesions, such as crosslinks or adducts. Common pathways to bypass replication blocks include 
trans-lesion synthesis, re-priming or rescue from a converging fork [95]. Alternatively, stalled 
forks can be processed by the DNA translocase SMARCAL1, which catalyzes fork regression and 
the generation of a “chicken foot” structure (Fig.7). This intermediate is protected by BRCA1, 
BRCA2 and FA [26] proteins from MRE11-dependent degradation [42, 43]. Recently, another 
DNA repair factor, 53BP1 was reported to bind reversed forks and protect from genomic instability 
[96]. The intermediate structures of reversed forks can be directly converted to active forks by 
reverse branch migration [97] or processed by BLM and WRN helicases, which migrate holiday 
junctions [98, 99].  
Another pathway for resolving stalled forks involves the nuclease MUS81, which is subject  
to cell cycle regulation [100]. Efficient cleavage by MUS81 requires the association with SLX4, 
which occurs in G2/M [101]. Thus, fork stalling in late S-phase or G2 is likely to be resolved by 
MUS81-mediated cleavage. Another aspect of cell cycle regulation is the activity of Wee1 kinase, 
which inhibits the endonuclease Mus81 [102]. Wee1 kinase activity decreases in late S-phase and 
G2 of the cell cycle [103]. Interestingly, the recruitment of the MUS81-SLX complex to stalled 
forks is facilitated by BRCA1 [104]. Cleavage by MUS81 results in a one-ended double strand 
break (DSB), which can be productively repaired only by HR, albeit 53BP1 competes with BRCA1 
for the break end. Repair of a one-ended DSB by NHEJ can result in lethal translocations. Thus, 





Figure 7. Main pathways for the processing of stalled replication forks. 
Stalled forks can be remodeled by SMARCAL1 and further processed in a cleavage-free manner 
to restart replication. Alternatively, stalled forks can be cleaved my MUS81-SLX4, which 
generates a one-ended double strand break, requiring repair by BRCA1-mediated HR. This 




1.9. THE FORK REMODELLER SMARCAL1 
SMARCAL1 (SWI/SNF family related, Matrix associated, Actin dependent Regulator of 
Chromatin, subfamily A-like1) is a DNA translocase with important functions in stalled replication 
fork remodeling and telomere maintenance [105]. Biallelic mutations in SMARCAL1 result in 
Schimke immuno-osseous dysplasia (SIOD), a multisystem disorder characterized by growth 
failure, brain malformations, atherosclerosis and deficiency in T-lymphocytes. Mice, lacking 
Smarcal1 are hypersensitive to topoisomerase inhibitors etoposide and irinotecan, as well as, the 
nucleotide reductase inhibitor hydroxyurea (HU) [106].The product of the human SMARCAL1 
gene is a 954 amino acid protein with an N-terminal RPA interacting motif, two HARP domains 
and a C-terminal helicase domain [105] (Fig.8). The interaction with RPA is required for the 
recruitment of SMARCAL1 to stalled replication forks [40] where SMARCAL1 acts as an 
annealing helicase to direct the binding of RPA-coated, complementary ssDNA strands to each 
other [107]. These activities generate DNA intermediates, which resemble holiday junctions and 
require protection by BRCA1 and other HR proteins from MRE11-dependent degradation [42, 
43]. The functions of SMARCAL1 are especially important at telomeres where G-quadruplex and 
T-loop structures frequently impede DNA replication. Accordingly, loss of SMARCAL1 has been 









Figure 8. Schematic of human SMARCAL1 protein. 
The RBD (RPA-binding domain) of SMARCAL1 is located at the N-terminal of the protein and 
spans the region from aa2 to aa30. The RBD is followed by a pair of HARP domains from aa260 
to aa303 and from aa327 to ss398. The helicase domain is located at the C-terminal of the protein 




















1.10. REPROGRAMMING TO PLURIPOTENCY 
Somatic cells can be reprogrammed to pluripotency by the ectopic expression of OCT4, 
SOX2, KLF4 and cMYC  [22]. The reprogrammed cell population, termed “induced pluripotent 
stem cells” (iPS) exhibits the hallmark characteristics of embryonic stem cells, such as ability to 
proliferate indefinitely and capacity to differentiate into any cell type. Since the landmark 
Yamanaka study [22], various reprogramming factor combinations have been developed, reviewed 
by Gonzalez et al. [109], including ones based entirely on small molecules [110]. The 
reprogramming process involves the generation of defined intermediate cell populations with 
characteristic transcriptional features [111]. To acquire pluripotency, cells first silence lineage-
specific genes and then proceed to activate embryonic factor promoters [112].  
The oncogene cMYC is not an essential component of the reprograming cocktail  [113], 
but it enhances the process substantially. Overexpression of cMYC causes replication stress and 
results in DNA damage [114]. However, increased DNA damage has been reported during the 
generation of iPS cells in the absence of cMyc (3 factors only Oct4, Sox2, Klf4) [24] and during 
reprogramming by nuclear transfer where no overexpression of transcription factors occurs [115]. 
Thus, DNA damage is a general reprogramming phenomenon, likely related to replication stress 
[116] and replication program remodeling [117], albeit the exact cause has not been formally 
established. The HR pathway for DSB repair plays an important role in iPS cell generation as 
Brca1 and Brca2 mutants have been shown to reprogram poorly [24]. Mutations or knockdown of 
other proteins involved in DNA damage repair, including Parp1 [118], Rad51 [24], FancC and 
FancA [119] as well as Atm [120] result in impaired reprogramming efficiency (Fig. 9). 
Conversely, ablation of the tumor suppressor p53 [121, 122] improves reprogramming by 
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compromising DNA-damage induced apoptosis signaling. Enhanced reprogramming has also been 
reported upon downregulation of Rb [21], which controls entry into the cell cycle.   
 
Figure 9. Factors which affect reprogramming efficiency.  
The ectopic expression of reprogramming factors during iPS cell generation leads to accumulation 
of DNA damage. Mutations in DNA damage signaling and repair pathways have a negative impact 
on reprogramming. Ablation of several tumor suppressors improves the efficiency of iPS cell 
generation. BRCA1 stands out as a tumor suppressor whose ablation impairs reprogramming.  









CHAPTER 2: BRCA1 AND 53BP1 MEDIATE REPROGRAMMING 
THROUGH DNA REPAIR PATHWAY CHOICE 
 
2.1. ABSTRACT 
Reprogramming to pluripotency is associated with increased levels of DNA damage which 
trigger the DNA damage response (DDR) pathway and require the functions of the homology-
directed repair (HDR) protein BRCA1. Here, we leverage the genetic interactions between 
BRCA1, its binding partner BARD1, the DNA translocase SMARCAL1 and the non-homologous 
end joining (NHEJ) factor 53BP1 to ascertain the relevance of stalled fork protection (SFP) and 
double strand break HDR in somatic cell reprogramming. Surprisingly, changes in stalled fork 
stability, which altered the levels of DNA damage marked by H2AX, were inconsequential for 
the transition to iPS cells, while deficiency in HDR alone impaired reprogramming. Ablation of 
53bp1 restored reprogramming in Brca1 mutants and also increased the efficiency of iPS cell 
generation in wild type cells. These results demonstrate that the DNA damage limiting to somatic 
cell reprogramming is a double strand break, which requires repair by homologous recombination.  
2.2. INTRODUCTION 
Somatic cells can be reprogrammed to pluripotency by the ectopic expression of four 
transcription factors OCT4, SOX2, KLF4 and cMYC, which are master regulators of the 
embryonic state [22]. The reprogrammed cell population, termed iPS cells, is endowed with the 
capacity to proliferate indefinitely, but also to differentiate into any specialized cell type in the 
adult organism. These characteristics make iPS cells uniquely suitable for disease modelling and 
drug discovery in vitro, as well as for the development of patient-specific cell replacement 
therapies. The overexpression of the OSKM reprogramming factors has been shown to result in 
increased levels of DNA damage [24], which was also reported in the absence of cMYC (OSK) 
and during reprogramming by nuclear transfer, where no overexpression of transcription factors 
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occurs [115]. These findings show that DNA damage is a general reprogramming phenomenon, 
likely related to replication stress [116] and replication program remodeling [117], albeit the exact 
cause has not been formally established. The HR pathway for double strand break (DSB) repair 
plays an important role in iPS cell generation as Brca1 and Brca2 mutants have been shown to 
reprogram poorly [24]. Mutations or knockdown of other proteins, involved in DNA damage 
repair, including Parp1 [118], Brca2 and Rad51 [24], FancC and FancA [119], FancD2 [123], as 
well as, Atm [120] have reduced reprogramming efficiency, suggesting that genome integrity plays 
a central role in somatic cell reprogramming. Conversely, ablation of tumor suppressors p53 [122, 
124], p21[121] and Rb [21] results in more efficient iPS cell generation. These observations 
indicate that there are shared molecular processes between reprogramming and oncogenic 
transformation, related to genome instability and overcoming the limitations in somatic cell 
proliferation. However, the source of reprogramming-induced DNA damage and the mechanisms 
of repair remain poorly understood as most factors affecting reprogramming efficiency, including 
BRCA1, exert multiple functions.            
BRCA1 is involved in the homology-directed repair (HDR) of DNA double strand breaks 
[125] and binds the strand invasion protein RAD51 [126]. Recent studies have reported a 
previously unrecognized function of BRCA1 in stalled replication fork protection (SFP). 
Heterozygous BRCA1 mutant cells show more extensive resection at stalled replication forks 
[127]. Stalled fork stability is conferred by the BRCA1/BARD1 heterodimer [62]. Point mutations 
in BARD1 have been reported to result in SF protection deficiency, manifested by reduced survival 
upon treatment with fork stalling agents MMC, hydroxyurea and the PARP inhibitor olaparib, 
though mutant mice are not cancer prone [62].  
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Here, we leverage the functional interactions of BRCA1 with BARD1, SMARCAL1 and 
53BP1 in a panel of mouse genotypes to determine the nature of the DNA damage generated during 
reprogramming and the mechanisms of repair. Specifically, we generated cells with combined 
HDR, SFP deficiency or single disruption of either double strand break HDR or SFP. We examined 
the relevance of SFP to reprogramming with two complementary strategies: disruption by point 
mutations in Bard1 and inactivation of one Brca1 allele. An additional model for the study of HDR 
and SFP functions of BRCA1 was developed by mutating the SNF-2 family translocase 
SMARCAL1, which remodels stalled replication forks to generate intermediate “chicken-foot” 
structures, degraded by MRE11 in the absence of BRCA1 [42]. Inactivation of SMARCAL1 
prevents fork degradation by interfering with the formation of the “chicken-foot” intermediate and 
selectively rescues SFP, without affecting HDR [42]. Furthermore, we restored HDR in Brca1 
mutant cells through inactivation of 53bp1, which competes for DNA ends with Brca1 and 
promotes repair by non-homologous end joining (NHEJ) [32, 80]. Our studies show that deficiency 
in stalled fork protection (SFP) is inconsequential to reprogramming. In contrast, we find 
decreased reprogramming efficiency in both HDR-SFP- and HDR- genotypes. Reprogramming is 
rescued upon restoration of HDR through mutation of 53bp1 in Brca1 mutant cells. Therefore, 
BRCA1 is required for the homology-directed repair (HDR) of replication stress-induced DNA 
damage during reprogramming. Surprisingly, stimulating HDR by disruption of 53bp1 also 
improved the reprogramming efficiency of wild type cells. This effect is not due to the role of 
53bp1 in p53-regulated transcription, but due to DNA repair pathway choice. Competition with 






2.3.1. REPROGRAMMING DEPENDS ON THE BRCT PHOSPHO-RECOGNITION 
PROPERTY OF BRCA1.  
 We previously reported that mouse fibroblasts, homozygous for a Brca1 truncation allele 
(Brca1tr/tr), generated by a 50-bp insertion into exon 11 [34], reprogram with reduced efficiency 
[24]. This Brca1 truncation produces a 924 amino acid hypomorphic protein, which lacks a portion 
of the DNA binding domain, the entire SQ cluster region and both copies of the C-terminal BRCT 
repeats. To test if BRCT phospho-recognition is required for somatic cell reprogramming, we 
generated fibroblasts triple homozygous for selected serine to alanine substitutions on Brca1 
partners Abraxas (S404), Bach1 (S994) and CtIP (S327), which interact with Brca1S1598 in the 
BRCT repeats. The phosphorylated isoforms of these three proteins associate with Brca1S1598 in 
a mutually exclusive manner and this interaction is abolished in the triple homozygous point 
mutant AbraxasS404AS404A, Bach1S994A/S994A, CtIPS327A/S327A genotype, referred to as 
AABBCC. To determine the reprogramming efficiency of the AABBCC genotype, we first collected 
control and mutant embryos for fibroblast derivation. We noticed that AABBCC embryos were 
smaller than their wild type littermates at E13.5 (Fig.10A). We infected primary fibroblasts from 
control, double homozygous (AABB, BBCC and AACC) and triple homozygous point mutant 
AABBCC embryos with doxycycline-inducible lentiviruses, which delivered the reprogramming 
factors Oct4, Sox2, Klf4 and cMyc. Reprogramming efficiency was assessed on day 20 by 
counting the number of colonies positive for alkaline phosphatase (AP), an early marker of 
pluripotency. This analysis revealed a 7-fold drop in reprogramming efficiency in the AABBCC 
genotype compared to control, which phenocopied the 6 to 8-fold reduction in reprogramming, 
recorded for Brca1tr/tr fibroblasts (Fig.1B, C). The double homozygous mutant AACC also 
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showed reduction in reprogramming efficiency (Fig.10D). This result demonstrates that BRCT 
phospho-recognition is required for reprogramming to pluripotency.  
 
Figure 10. BRCT phospho-recognition is required for reprogramming. A). Size and 
morphology of E13.5 embryos from the AbraxasS404A/S404A, Bach1S994A/S994A, 
CtIPS327A/S327A genotype collection. Each genotype included 3 to 9 embryos and statistical 






Figure 10 (continued). B). and C). Alkaline phosphatase (AP) staining and quantification on 
reprogramming day 20. Statistical analysis was performed with an unpaired, 2-tailed t test; n = 5 
per genotype, except for AABBCC (AbraxasS404A/S404A, Bach1S994A/S994A, CtIP327A/327A), 










Figure 10 (continued). D). AP staining and quantification for the ABC genotype collection. Data 
was collected from 3 to 7 biological and experimental replicates, except for AABBCC where only 
2 data points were available. Statistical analysis was performed with one-way ANOVA and 







The deficiency in BRCT phospho-recognition in the AABBCC point mutant disrupts both 
the function of Brca1 in the homology directed repair (HDR) and its role in stalled replication fork 
protection (SFP). To distinguish between these two roles and to determine the specific type of 
DNA damage limiting to somatic cell reprogramming, we generated a panel of primary mouse 
fibroblasts with single and combination mutations in stalled replication fork protection (SFP) and 
homology-directed repair (HDR) of DNA double strand breaks (Table 1).  
Table 1. Reprogramming genotype collection. 
Reprogramming phenotype and tumor susceptibility are indicated for each genotype-phenotype 
pair. * To be confirmed. TBD = to be determined.  
Genotype Phenotype Cancer Prone Reprogramming Phenotype 
Bard1K607A/+ HR+ SF- No No 
Bard1K607A/K607A HR+ SF- No No 
Bard1S563F/+ HR+ SF- No No 
Bard1S563F/S563F HR+ SF- No No 
Brca1tr/+ HR+ SF- No No 
Smarcal1+/- HR+ SF+  No 
Smarcal1-/- HR+ SF+  No 
Brca1tr/+, Smarcal1+/- HR+ SF- *  No 
Brca1tr/+, Smarcal1-/- HR+ SF+  No 
Brca1tr/tr HR- SF- Yes reduced  
Brca1tr/tr, Smarcal1+/- HR- SF- *  reduced 
Brca1tr/tr, Smarcal1-/- HR- SF+  reduced 
53bp1+/- HR+ SF+  improved 
53bp1-/- HR+ SF+ Yes  improved  
Brca1tr/+, 53bp1+/- HR+ SF+ *  improved 
Brca1tr/+, 53bp1-/- HR+ SF+ *  improved 
Brca1tr/tr, 53bp1+/- HR+ SF+ *  rescue 
Brca1tr/tr, 53bp1-/- HR+ SF+ * No rescue 
AABB TBD No No 
BBCC TBD No No 
AACC TBD No reduced 
AABBCC HR- SF- No reduced 
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2.3.2. DISRUPTION OR RESCUE OF STALLED FORK PROTECTION (SFP) ALTERS THE 
LEVELS OF DNA DAMAGE WITHOUT AFFECTING REPROGRAMMING EFFICIENCY.  
To determine if stalled fork protection (SFP) is required for reprogramming, we first 
examined mutations which compromise the function of Brca1 in SFP without affecting homology-
directed repair (HDR). The SFP- genotype set included a heterozygous Brca1 truncation 
(Brca1tr/+), [34], as well as, heterozygous and homozygous Bard1S563F point mutants. Cells 
mutant for Bard1 (BRCA1 associated RING domain 1) are HDR-proficient, but sensitive to fork 
stalling agents such as hydroxyurea [62]. To determine the consequence of SFP deficiency on 
DNA damage during reprogramming, we quantified foci for γH2AX, phospho RPA(S33), and 
53BP1 on day 5 of reprogramming. We found a 1.5-fold increase in the mean number of γH2AX 
foci per cell in both SFP-deficient genotypes, Brca1tr/+ and Bard1S563F/S563F (Fig.11A). Foci, 
marked by phospho RPA(S33), phosphorylated by ATR in late S and G2 [64, 65] showed 
accumulation of ssDNA in the context of SFP deficiency. Notably, Brca1tr/+ mutants had a 3 to 
4-fold increase in phospho RPA(S33) foci compared to the SFP proficient controls (Fig.11B). 
Albeit, Brca1tr/+ fibroblasts accrued higher numbers of γH2AX foci, the mean number of 53BP1 
foci per cell did not increase significantly (Fig.11C). Therefore, replication stress is increased in 
SFP deficient cells during reprogramming, though it does not necessarily result in a double strand 
break bound by 53BP1. To determine whether the increase in γH2AX and phospho RPA(S33) foci 
was consequential for cell proliferation, we treated cells with the cytoplasmic dye CFSE, which is 
diluted through cell division, but retained in arrested cells. We noted no differences in proliferation 
on day 5 of reprogramming in the SFP mutants (Fig.11D and Fig.12A). Furthermore, deficiency 
in stalled fork protection had no consequences on embryo growth, as shown by the normal size 
and morphology of SFP- E13.5 embryos (Fig.12B). Despite an increase in DNA damage, SFP- 
genotypes (Brca1tr/+, Bard1S563F/+ and Bard1S563F/S563F) and the SFP+ control 
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reprogrammed equally well as shown by the number of alkaline phosphatase (AP) positive 
colonies on reprogramming day 20 (Fig.11E). This result was further confirmed by the 
reprogramming efficiency of two additional Bard1 SF- mutants, Bard1K607A/+ and 
Bard1K607A/K607A, which was not different from controls (Fig.12C). These results indicate that 
the function of Brca1 in stalled fork protection (SFP) is dispensable for reprogramming. Therefore, 
elevated DNA damage, measured by an increase in γH2AX foci in the SFP-genotypes, does not 
directly correlate with impaired reprogramming efficiency.  
 
Figure 11. Stalled fork protection deficiency increases DNA damage but does not impair 
reprogramming. A). Immunofluorescence and quantification for double strand break (DSB) 
marker γH2AX. Foci were counted on reprogramming day 5 in fibroblasts derived from 2-3 
different embryos per genotype (>200 cells). Statistical analysis was performed with one-way 
ANOVA and Sidak’s multiple comparisons test. B). Immunofluorescence and quantification of 
phospho RPA(S33)/γH2AX double positive foci. Statistical significance was evaluated with an 




Figure 11. (continued) C). Immunostaining and quantification of 53BP1 foci. The analysis 
included 2-3 biological replicates per genotype (>200 cells) and statistical analysis was performed 
with an unpaired two-tailed t-test. D). Number of CFSE positive cells relative to wild type control. 
Data was collected from 2-3 biological replicates per genotype and analyzed with one-way 












Figure 11. (continued) E). Alkaline phosphatase (AP) staining and reprogramming efficiency 
quantification. The number of AP positive colonies was first normalized to the percentage of 
infected cells and shown as a ratio to wild type. Data from 3-9 biological and experimental 
replicates per genotype was analyzed by one-way ANOVA.; All comparisons in the ANOVA 













Figure 12. Compromising SF has no effect on development or reprogramming.  
A). Flow cytometry plots of CFSE cytoplasmic dye retention. Serum starved cells exhibit a bright 






Figure 12 (continued) B). Morphology and size of E13.5 embryos. In each genotype, the area of 
11-13 embryos were measured, except for Bard1563F/S563F for which only one embryo was 
available. Statistical analysis was performed with one-way ANOVA and Sidak’s multiple 




Figure 12. (continued). C). Alkaline phosphatase (AP) staining and quantification of 
reprogramming efficiency for 3 to 7 biological and experimental replicates per genotype. The 
results are shown as a ratio to wild type after normalization to percent infected cells. Statistical 









The homozygous Brca1 truncated mutant Brca1tr/tr is deficient in both HR and SF. 
Separation of function for the roles of BRCA1 in homology-directed repair (HDR) and stalled fork 
protection (SFP) can be achieved through loss of function of the SNF2-family translocase 
SMARCAL1 [42]. Depleting SMARCAL1 rescues the SFP proficiency of BRCA1 mutant cells 
by preventing the formation of a chicken-foot structure, which is a substrate for MRE-11 
dependent degradation. BRCA1 mutant cells depleted for SMARCAL1 remain HDR deficient 
[42]. The HDR-SFP- Brca1tr/tr cells accumulated high levels of DNA damage on day 5 of 
reprogramming, marked by a 2-fold increase in the mean number of γH2AX foci per cell (Fig. 
13A). This was higher than the 1.5-fold increase, recorded for the SFP- deficient genotypes on 
Fig.11A. The number of γH2AX foci was significantly reduced upon rescue of SFP protection in 
Brca1/Smarcal1 double mutant cells, though it remained higher than in controls (Fig.13A). 
Similarly, deficiency for both HDR and SFP in Brca1 mutant cells resulted in a 5 to 6-fold increase 
in the number of phospho RPA(S33) foci (Fig.13B). This was higher than the 3 to 4-fold increase 
recorded for the SFP- genotype Brca1tr/+ on Fig.11B. The number of phospho RPA(S33) foci 
was greatly reduced in the absence of Smarcal1, but remained 2-fold higher than in the controls 
(Fig.13B). To evaluate the SFP deficiency of Brca1tr/tr cells during reprogramming, we 
performed DNA fiber analysis through incubation with CldU, followed by IdU and subsequent 
treatment with hydroxyurea (HU) to induce fork stalling. A decrease in the mean length of the IdU 
tract relative to CldU shows excessive fork degradation. Stalled forks were frequently degraded in 
the HDR-SFP- genotype while loss of Smarcal1 rescued the phenotype (Fig.13C). Concordant 
results were obtained using the G-quadruplex stabilizing compound pyridostatin (PDS) which 
stalls replication forks in G-rich regions of the genome (Fig.14A). The proliferation capacity of 
the different genotypes during reprogramming was tested by incubation with the cytoplasmic dye 
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CFSE, which is rapidly diluted by cycling cells. This analysis revealed a proliferation defect in the 
HDR-SFP- genotype, which persisted despite the rescue of SFP in Brca1tr/tr, Smarcal1-/- cells 
(Fig.13D and Fig.14B). Brca1tr/tr embryos were delayed in development, and were not rescued 
by restoration of SFP through Smarcal1 deletion (Fig.14C). Ablation of Smarcal1 alone had no 
effect on proliferation capacity or development (Fig.13D and Fig.14C). Apoptosis signaling in the 
different genotypes was evaluated by flow cytometry for Annexin V and propidium iodide (PI) on 
reprogramming day 5. Combined HDR-SFP- deficiency led to accumulation of both early and late 
apoptotic cells in the Brca1tr/tr genotype, which persisted in Brca1tr/tr, Smarcal1-/- mutants, 
despite protection of SF (Fig.13E and Fig.14D).The reprogramming efficiency of HDR-SFP- 
Brca1tr/tr cells was severely impaired (6 to 8-fold lower) compared to the wild type control 
(Fig.13F and Fig.14E). Importantly, restoring SF in Brca1-deficient cells through the genetic 
inactivation of Smarcal1 did not rescue their poor reprogramming phenotype (Fig.13F and 
Fig.14E). Ablation of one or both Smarcal1 alleles alone or in combinations with the Brca1tr/+ 
genotype had no effect on iPS cell generation (Fig.13F and Fig.14E). These findings show that 
Brca1 is required for reprogramming for the homology-directed repair (HDR) of DSBs, not 
through its role in stalled replication fork protection (SFP). Though γH2AX-marked DNA damage 
was partially reduced in Brca1/Smarcal1 double mutant cells, reprogramming efficiency was not 
increased. Therefore, not all DNA damage marked by γH2AX is equally consequential to 








Figure 13. The function of Brca1 in HDR is required for reprogramming.  
A). Immunofluorescence and quantification for γH2AX foci on reprogramming day 5. Foci were 
counted in 3 biological replicates per genotype with a total number of at least 430 cells per 
genotype. Statistical analysis was performed with an unpaired, two-tailed Student’s t test. *p < 




Figure 13. (continued) B). Staining and quantification for phospho RPA(S33)/γH2AX double 
positive foci. Data was collected from 3 biological replicates per genotype (>145 cells per 
genotype) and the statistical significance was determined with an unpaired, two-tailed Student’s t 










Figure 13. (continued) C). DNA fiber analysis in a fork stalling assay with hydroxyurea (HU). 
At least 170 DNA fibers were measured per genotype from 2-3 biological replicates and analyzed 






Figure 13. (continued) D). Cell proliferation analysis with CFSE dye. Data was pooled from 2-4 
biological and experimental replicates per genotype. Statistical significance was determined with 







Figure 13. (continued) E). Apoptosis analysis with Annexin V and propidium iodide (PI). Data 
was collected from 3 biological replicates per genotype and analyzed by one-way ANOVA and 











Figure 13. (continued) F). Alkaline phosphatase staining and quantification of reprogramming 
efficiency. Data was collected from 3-5 biological and experimental replicates per genotype, 
except for the Smarcal1-/- and the AbraxasS404A/S404A, Bach1S994A/S994A, CtIP327A/327A 
genotypes which had 2 data points each. Reprogramming efficiency was normalized to percent 
infected cells and is shown as a ratio to wild type control. Statistical analysis was performed with 
one-way ANOVA. All comparisons in the ANOVA analyses were made with Sidak’s multiple 







Figure 14. Loss of HR has negative consequences for development and reprogramming. 
A). DNA fiber analysis in a fork stalling assay with pyridostatin (PDS). Data was collected from 
2-3 biological replicates (>180 fibers per genotype in total) and analyzed with one-way ANOVA 










Figure 14. (continued) B). Flow cytometry plots for CFSE cytoplasmic dye. Serum starved and 




Figure 14. (continued). C). Size and morphology of E13.5 embryos from the Brca1/Smarcal1 
genotype collection. For quantification by embryo area size, each genotype included 3-10 embryos 
except Brca1tr/+, Smarcal1-/- and Brca1tr/tr, Smarcal1-/- for which 2 embryos per genotype were 









Figure 14.  (continued) D). Flow cytometry for Annexin V-FITC and propidium iodide (PI). Early 
apoptotic cells stain for Annexin V only, while late apoptosis is marked by double staining for 






















2.3.3. REPROGRAMMING EFFICIENCY IS DETERMINED BY THE BALANCE OF DNA 
DSB REPAIR PATHWAY CHOICE 
Ablation of 53bp1 in Brca1 mutant cells has been reported to re-establish their HDR 
proficiency [35]. In wild type cells, the ablation of 53BP1 is used to increase gene targeting by 
homologous recombination [128] as 53BP1 promotes NHEJ and inhibits BRCA1-mediated HDR 
in a competitive manner [32]. To assess whether rescuing the HDR function of Brca1tr/tr cells 
restores reprogramming to wild type levels, we harvested fibroblasts from embryos deficient in 
both Brca1 and the NHEJ repair factor 53bp1 (Table 1). Evaluation of DNA damage on 
reprogramming day 5 revealed that removing a single copy of 53bp1 is sufficient to reduce 
significantly the mean number of γH2AX foci per cell in the Brca1tr/tr genotype (Fig. 15A). 
Further reduction was noted when both alleles of 53bp1 were eliminated (Fig. 15A). There was no 
detectable difference between the number of γH2AX foci per cell in the control and the Brca1tr/tr 
genotype with either heterozygous or homozygous inactivation of 53bp1 (Fig. 15A). Loss of one 
or both copies of 53bp1 also reduced the accumulation of phospho RPA(S33) foci in Brca1 
deficient cells (Fig. 15B). The mean number of phospho RPA(S33) foci in Brca1tr/tr mutants on 
a 53bp1 null background was not significantly different from the wild type control, though it 
remained higher in heterozygous 53bp1 mutant, Brca1 deficient cells (Fig. 15B). To determine the 
effect of 53bp1 disruption on fork stability, we performed a fork-stalling assay with hydroxyurea. 
Fiber analysis revealed that ablating one or both copies of 53bp1 rescues the SFP function of the 
Brca1tr/tr genotype as shown by the restored length of the IdU track, relative to CldU (Fig.15C). 
Concordant results were recorded for a complementary fork-stalling assay with pyridostatin 
(Fig.16A). Restoration of HDR competence of the different genotypes was assessed by 
CRISPR/Cas9-mediated  targeting of a zsGreen repair template to the Hsp90 locus in mouse 
induced pluripotent stem (iPS) cells (Table 2) as described in Mateos-Gomez et al. [129]. This 
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strategy evaluates HDR proficiency based on the presence of a genomically integrated zsGreen 
template, which generates a fluorescent protein, detected by flow cytometry. The HDR deficiency 
of Brca1tr/tr iPS cell lines was confirmed by a 2-fold reduction in the number zsGreen positive 
cells, which was restored to wild type levels on a 53bp1-/- background (Fig.15D and Fig.16B). 
Inactivation of 53bp1 also improved the proliferation capacity of the HDR-SFP- genotype as 
shown by a reduction in the number of cells that retain the CFSE cytoplasmic dye (Fig.15E and 
Fig.16C). The positive effect on proliferation had developmental consequences, revealed by the 
complete rescue of the reduced embryo size in the Brca1tr/tr mutants upon loss of 53bp1 
(Fig.16D). Heterozygous or homozygous ablation of 53bp1 in wt cells did not affect proliferation 
(Fig.15E) or development (Fig.16D). Loss of 53bp1 also had pronounced effects on the apoptotic 
rates of Brca1tr/tr mutants (Fig.15F). The number of early apoptotic cells in HDR-SFP- Brca1tr/tr 
genotype was reduced 2-fold on a 53bp1 heterozygous background and 4-fold when 53bp1 was 
fully removed (Fig.15F and Fig.16E). A similar reduction was noted for late apoptotic cells, 
positive for both Annexin V and PI (Fig.15 and Fig.16E). Ablation of 53bp1 alone did not cause a 
detectable increase in apoptosis (Fig.15F). Importantly, removal of one or both copies of 53bp1 
rescued the poor reprogramming efficiency of Brca1tr/tr cells (Fig.15G and Fig.16F). Disruption 
of a single copy of 53bp1 resulted in a 5-fold improvement in reprogramming efficiency (Fig.15G), 
while removing both copies resulted in 11-fold increase and a complete rescue in the number of 
alkaline phosphatase positive colonies (Fig.15G). We noted that 53bp1 loss also consistently 
resulted in a significant increase in reprogramming of HDR+SFP+ wild type cells as well of the 
SFP- deficient Brca1tr/+ genotype (Fig.15G and Fig.16F). The improvement for wild type and 
Brca1tr/+ cells was a 2-fold increase upon complete loss of 53bp1 (Fig.15G and Fig.16F). 
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Therefore, and unlike previously reported [130], ablation of 53bp1 increases reprogramming 
efficiency in all genetic contexts examined. 
 
Figure 15. Restoration of HDR rescues impaired reprogramming efficiency.  
A). Immunofluorescence staining and quantification of γH2AX foci on day 5 of reprogramming. 
Data was collected from >400 cells per genotype and analyzed with one-way ANOVA and Sidak’s 








Figure 15.  (continued) B). Staining and quantification for phospho RPA(S33)/γH2AX double 
positive foci. For each genotype at least 145 cells were analyzed and statistical significance was 












Figure 15. (continued) C). DNA fiber analysis in a fork stalling assay with hydroxyurea. For each 
genotype >120 fibers were measured and statistical significance was calculated with one-way 




Figure 15. (continued) D). CRISPR/Cas9 based HR assay with 2-3 induced pluripotent stem (iPS) 
cells lines per genotype from the indicated genotypes. The data is shown as a ratio to wild type 
control and was analyzed with an unpaired two-tailed t-test. E). Analysis of cell proliferation with 
CFSE cytoplasmic dye. Data from 2 to 5 biological and experimental replicates per genotype was 
pooled and statistical significance was measured with one-way ANOVA and Sidak’s multiple 









Figure 15. (continued) F). Apoptosis analysis with Annexin V and propidium iodide. Data was 
collected from 3 biological replicates per genotype and evaluated with one-way ANOVA and 









Figure 15. (continued) G). Alkaline phosphatase (AP) staining and quantification of 
reprogramming efficiency for the Brca1/53bp1 genotype collection. Data from 4-9 biological and 
experimental replicates was normalized to infection efficiency and is shown as a ratio to wild type 
control. Statistical analysis was performed with one-way ANOVA.; All comparisons in the 














Table 2. iPS cell line collection. 
List of mouse iPS cell lines, derived from fibroblasts of the indicated genotypes. Colonies were 














Genotype # of Cell lines  Cell Line IDs 
wt 6 BS2-1A, BS2-1B, BS3-4A, BS3-4B, BS3-7A, BS3-7B 
Brca1tr/+ 5 BS1-2B, BS1-2C, BS4-3A, BS4-3B, BS4-9B 
Smarcal1+/- 6 BS2-5A, BS2-5B, BS2-6A, BS2-6B, BS4-1A, BS4-1B 
Smarcal1-/- 6 BS6-2A, BS6-2B, BS6-3A, BS6-3B, BS6-6A, BS6-6B 
Brca1tr/+, Smarcal1+/- 6 BS2-3A, BS2-3B, BS3-1A, BS3-1B, BS4-2A, BS4-2B 
Brca1tr/+, Smarcal1-/- 6 BS2-2C, BS2-2D, BS2-2E, BS6-1A, BS6-1B, BS6-5A 
Brca1tr/tr 4 BS2-4A, BS2-4B, BS4-6B, BS4-8A 
Brca1tr/tr, Smarcal1+/- 5 BS3-2A, BS3-2B, BS3-5B, BS4-7A, BS4-7B 
Brca1tr/tr, Smarcal1-/- 6 BS3-3A, BS3-3B, BS4-5A, BS4-5B, BS6-7A, BS6-7B 
53bp1+/- 5 BP2-1B, BP2-1C, BP2-5A, BP2-5B, BP6-1A 
53bp1-/- 10 BP5-3E, BP6-2A, BP6-2B, BP6-2C, BP6-2E, BP6-7A, BP6-
7C, BP6-7D, BP6-7E, BP6-7F 
Brca1tr/+, 53bp1+/- 3 BP2-4B, BP6-4A, BP6-4B 
Brca1tr/+, 53bp1-/- 3 BP3-9B, BP4-6A, BP5-2A 
Brca1tr/tr, 53bp1+/- 4 BP2-8A, BP3-7A, BP5-1A, BP5-1B 
Brca1tr/tr, 53bp1-/- 10 BP2-9B, BP4-5A, BP4-5B, BP4-5C, BP4-5D, BP4-5D 




Figure 16. Restoration of HDR rescues development and reprogramming. 
A). DNA fiber assay of replication stalled with pyridostatin (PDS). At least 180 DNA fibers were 
measured per genotype and statistical significance was evaluated with one-way ANOVA and 









Figure 16. (continued) B). Flow cytometry plots from iPS cell lines of the indicated genotypes in 














Figure 16. (continued) C). Flow cytometry plots of cells incubated with the CFSE cytoplasmic 




















Figure 16. (continued) D). Size and morphology of E13.5 embryos from the Brca1/53bp1 
genotype collection. Each genotype included 3-11 embryos. Statistical analysis was performed 









Figure 16. (continued) E). Flow cytometry plots from apoptosis analysis with Annexin V and 
propidium iodide (PI). Cells positive for Annexin V are in early apoptosis, while late apoptotic 





























The integrity of the genome of reprogrammed stem cells is an important determinant of 
their utility in stem cell research and therapy. From studies in two different reprogramming 
systems, iPS cells and somatic cell nuclear transfer, we know that reprogramming results in 
increased DNA damage and replication stress marked by H2AX [24, 116, 131]. Therefore, a 
detailed understanding of the type of DNA damage and the repair pathways required is important.  
Replication stress signals can arise from stalled forks, which result in the formation of 
excessive single stranded DNA and double strand breaks. Stalled replication forks can be resolved 
by several pathways, including re-priming, regression with template switching, and break induced 
replication, reviewed in [95]. In this study, we use separation of function mutants for the roles of 
Brca1 in stalled replication fork protection (SFP) and homology-directed repair (HDR) to assess 
their importance in reprogramming. Our data shows that despite a significant increase in γH2AX 
and phospho RPA(S33) foci, three genotypes deficient for SFP, Brca1tr/- and two Bard1 mutants, 
did not experience any reduction in reprogramming efficiency.  
Stalled forks in BRCA1 mutant cells are degraded after formation of a four-way 
intermediate structure, termed “chicken foot”, which is generated by the fork remodelers 
SMARCAL1, ZRANB3 and HLTF [42]. The inactivation of SMARCAL1 impairs fork regression 
and the formation of the branched intermediate, thereby preventing fork degradation in the absence 
of BRCA1. [42]. Leveraging this interaction, we tested the role of SFP in reprogramming further 
by ablating Smarca1l in Brca1 mutants. Loss of Smarcal1 in Brca1tr/tr cells reduced the numbers 
of both γH2AX and phospho RPA(S33) foci, indicating that the rescue of SFP lowers replication 
stress during reprogramming. Despite this decrease, Brca1tr/tr, Smarcal1-/- mutants were 
impaired in reprogramming, comparable to the Brca1tr/tr genotype. Our studies thus far allowed 
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for two important conclusions: first, not all replication stress-associated DNA damage affects 
reprogramming efficiency. And second, while stalled fork protection is dispensable for 
reprogramming, homology-directed repair is not: Brca1tr/tr, Smarcal1-/- cells are deficient 
specifically for the HDR, but not the SFP function of BRCA1 and reprogram poorly.  
To test whether restoring HDR improves the poor reprogramming of Brca1tr/tr mutants, 
we made use of the genetic interaction with 53bp1. The DNA repair factor 53BP1 acts together 
with RIF1 in a competitive and antagonistic manner to BRCA1-CtIP to inhibit the resection of 
double strand breaks [80]. Inactivation of 53bp1 in Brca1 mutant cells has been previously shown 
to rescue their HDR competence [35]. Loss of one allele of 53bp1 in Brca1tr/tr cells was sufficient 
to reduce the number of γH2AX foci to wild type levels, and also significantly lowered the number 
of phospho RPA(S33) foci. Notably, this also restored the reprogramming efficiency of Brca1tr/tr 
cells to nearly wild type levels. Complete 53bp1 loss fully rescued the efficiency of iPS cell 
generation in the absence of Brca1. Surprisingly, improved reprogramming upon disruption of 
53bp1 was also noted for wild type cells as well as the heterozygous SFP- deficient Brca1tr/+ 
genotype. This result challenges a previous study which reported a 2-fold reduction in iPS cells 
generation for 53bp1-/- mouse fibroblasts compared to controls [130]. Marion et. al did not publish 
error bars or statistical analysis of the reported difference. The strength of our conclusion comes 
from examining the consequences of 53bp1 loss in three different genotypes-wild type, Brca1tr/+ 
and Brca1tr/tr, all of which reprogram better in the absence of 53bp1. Furthermore, we show a 
dose dependent increase in reprogramming efficiency, which is detectable in 53bp1+/- cells, but 
more pronounced on the null background. Importantly, this result was universal across all three 
genotypes, demonstrating that 53bp1 suppresses reprogramming to pluripotency. Since Brca1 and 
53bp1 compete to determine repair pathway choice, the absence of 53bp1 in wild type cells might 
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enhance the efficiency of HDR. This idea has been corroborated by CRISPR/Cas9 gene targeting 
studies which have reported improved rates of HR-mediated genome editing by inhibition of 
53BP1 [128].  
In addition to its role in DSB repair by non-homologous end joining, 53BP1 has a separate 
function in the stimulation of p53-dependent transcription [92]. Loss of 53BP1 has been reported 
to impair the induction of p21, as well as, pro-apoptotic targets BAX and PUMA/BBC3 in human 
metastatic adenocarcinoma cells [92]. Loss of p53 or downregulation of p21 improves iPS cell 
generation [121], providing an alternative mechanism by which ablation of 53bp1 could increase 
reprogramming. However, another study showed normal stabilization of p53 in 53bp1-/- mouse 
thymocytes and upregulation of p21 in response to IR [93]. In our experimental system-mouse 
embryonic fibroblasts, we did not note any changes in proliferation or apoptosis in 53bp1+/- or 
53bp1-/- cells and found normal induction of p21 in both 53bp1 mutant cells (data not shown). 
Therefore, the improvement in reprogramming efficiency in the absence of 53bp1 is not due to 
compromised induction of p53 targets. 
The prominent role of HDR during iPS cell generation was further corroborated by studies 
of triple homozygous phosphoserine point mutants Abraxas S404A/S404A, Bach1S994A/S994A, 
CtIPS327A/S327A. In their phosphorylated form, these proteins interact with Brca1 at S1598 
which is required for tumor suppression [11]. While Brca1tr/tr is a hypomorph lacking the entire 
BRCT domain, the AABBCC mutant offers a highly specific disruption of HR. We noted a 
reduction in reprogramming efficiency for AABBCC, as well as the double homozygous 
phosphoserine point mutant, AACC. This shows that the phospho-dependent interaction between 
CtIP and Brca1 facilitates reprogramming, though revealing this effect also required a sensitized 
system with a phosho-mutation in Abraxas. In line with this result, downregulation of CtIP has 
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been previously shown to have a negative effect on iPS cell generation [25]. The phosphorylation 
of CtIP is cell cycle regulated and S327 is phosphorylated by Cdk1 in G2 [132]. This points out 
that repair by homologous recombination becomes relevant in G2 during reprogramming.  
Our observations collectively indicate that the limiting factor for reprogramming to 
pluripotency is a one-ended double strand break which requires homology-directed repair (Fig.17). 
Stalled replication forks are cleaved by endonuclease Mus81, which is regulated in a cell-cycle 
dependent manner by the Wee1 kinase [102]. In early S-phase, converging forks and alternative 
mechanisms of replication fork restart are available to cope with replication stress, which allows 
reprogramming despite increased DNA damage. In G2 of the cell cycle, HDR becomes limiting 
due to a paucity of origins in late replicating regions [133] and increased cleavage of stalled forks 
by Mus81. Replication stress in late replicating regions is hence most consequential. Consistent 
with this model, copy number variations in induced pluripotent stem (iPS) cells occur at common 
late replicating fragile sites [134, 135].  
Several studies have pointed out the parallels between reprogramming and tumorigenesis 
[136, 137].The deletion of tumor suppressors p53, p21 and Rb facilitate both reprogramming and 
abnormal cell transformation. In this work, we demonstrate that the primary inhibitor of 
reprogramming is a double strand break (DSB), repaired by HR. Homology-directed repair has 
slow kinetics [71] and is counteracted by nonproductive repair mechanisms. Unresolved repair 
intermediates can persist through G2, into mitosis and the next G1 [138]. The inheritance of such 
damage determines further cell cycle progression through activation of p21 and Rb [139, 140]. 
Therefore, an unrepaired replication-associated DSB is highly consequential and acts upstream of 
tumor suppressors p21, p53 and Rb to repress cell type transitions. 
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 In contrast to the deletions of p21, Rb or p53, loss of the tumor suppressor Brca1 severely 
impairs reprogramming. The function of BRCA1 in the maintenance of genomic stability through 
HDR is required for both reprogramming and tumor suppression. Mice with HDR deficiency are 
tumor prone [11]. The role of Brca1 in stalled fork protection (SFP) is dispensable for 
reprogramming, as well as, for tumor suppression [62]. Similarly, separation of function mutations 
in BRCA2 show that the HDR function, but not the SFP function is required to prevent 
chromosome fragility [141]. Importantly, loss of 53bp1 restores HDR and reduces the tumor 
incidence in Brca1tr/tr animals [33], and in our system we show that it also rescues 
reprogramming. Interestingly, some BRCA1-deficienct cancers inactivate 53BP1, which restores 
HDR competence [89, 142]. This BRCA1 paradox, where HDR is required for tumor suppression, 
but also enables tumor growth and mediates cell transformation during reprogramming remains 
unresolved. A plausible solution is provided here: BRCA1 is required to maintain the integrity of 
the regions, which generate replication-associated double strand breaks, activate downstream 





















Figure 17. One-ended DSBs limit somatic cell reprogramming. 
One-ended double strand breaks (DSBs), resulting from replication-associated DNA damage 
during reprogramming require repair by homologous recombination (HR). The competing repair 
pathway, non-homologous end joining (NHEJ), is not productive and impairs reprogramming. The 
presence of DSBs results in the activation of tumor suppressors p53, p21 and Rb which inhibit 
reprogramming. Ablation of the NHEJ factor 53bp1 or the tumor suppressors p53, p21, Rb results 









2.5. MATERIALS AND METHODS 
 
2.5.1. Animal breeding 
To generate Bard1 mutants, heterozygous Bard1S563F/+ and Bard1K607A/+ females on 
a C57BL/6J background, described in Billing et al. [62] were bred to males of the same genotypes. 
The Brca1/Smarcal1 genotype collection was created from intercrosses between Brca1tr/+, 
Smarcal1+/- animals of mixed C57BL/6J and 129Sv background. The Brca1tr/+ allele is 
described in [34]. Mice, mutant for Smarcal1 were obtained from the International Mouse 
Phenotyping Consortium (IMPC). The Brca1/53bp1 genotype panel was generated from 
intercrosses between Brca1tr/+, 53bp1+/- males and females on a mixed C57BL/6J and 129Sv 
background. For the AbraxasS404A/Bach1S994A/CtIPS327A genotype collection, referred to as 
ABC, we first crossed mixed background (C57BL/6J and 129Sv) AABB mice to CC to generate F1 
triple heterozygous A+B+C+ animals. The F1 generation of A+B+C+ was intercrossed to obtain 
the different combinations of double homozygous mutants. To generate triple homozygous 
phosphoserine mutants, F2 A+BBCC males were crossed to F2 A+BBCC or A+BBC+ females. 
From the A+BBCC x A+BBCC crosses, 1 of 9 embryos was triple homozygous mutant (expected 
mendelian ratio 1/4). One additional triple homozygous mutant embryo was found from the triple 
heterozygous intercrosses (A+B+C+ x A+B+C+) which produced 69 embryos (expected 
mendelian ratio 1/64). 
2.5.2. Fibroblast derivation and genotyping 
To derive fibroblasts for reprogramming, we harvested E13.5 mouse embryos from the 
above described crossed and processed them as follows: the embryo head, limbs and all internal 
organs were removed by dissection and the remaining tissue was mechanically dissociated with 
surgical scissors. This step was followed by a 10-15min incubation with TrypLE at 37C (Thermo 
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Fisher Scientific #12605036), trypsin inactivation with media and a 5min centrifuge spin. The cells 
from a single embryo were then plated in one 10cm dish and grown in MEF media, consisting of 
DMEM HG (Thermo Fisher Scientific #10569010), supplemented with 10% FBS (Atlanta 
Biologicals #S11150), Glutamax (Thermo Fisher Scientific #35050079) and PenStrep (Thermo 
Fisher Scientific 15140163). Cells were split once to P1 and frozen down for reprogramming 
experiments. The sequences of all genotyping primers are provided in Table 3.  
 
Table 3. Sequences of genotyping primers. 





























































2.5.3. Virus preparation and infection 
 This study used a doxycycline inducible lentiviral system, consisting of Tet-O-FUW-
OSKM (Addgene #20321) and FUW-M2rtTA (Addgene # 20342). Lentivirus was prepared in 
293T cells by transfection of plasmids with Jetprime transfection reagent (VWR #89129-922) as 
outlined in the manufacturer’s instructions. Briefly, Tet-O-FUW vectors were transfected together 
with the envelope and packaging plasmids pMD2VSVG (Addgene #12259) and psPax2 (Addgene 
# 12260) into 293T cells plated on collagen-coated dishes. Fresh antibiotic-free media DMEM HG 
(Thermo Fisher Scientific #10569010), supplemented with 15% FBS (Atlanta Biologicals 
#S11150) and Glutamax (Thermo Fisher Scientific #35050079) was provided 16 to 20h post 
transfection. Viral supernatant was collected on each of the following two days and kept at 4C for 
up to 4 days. Prior to infection, titer from the two collection days was pooled and filtered through 
a 40uM cell strainer (Fisher Scientific #08-771-1).  
 For infection, P1 mouse embryonic fibroblasts (MEFs) were thawed and plated at 1x106 
cells per 10cm dish on the previous day. Infection proceeded in two rounds with 8h to 9h in 
between. Briefly, cells were incubated with an OSKM/rtta virus mix (1:1), supplemented with 
8ug/ml protamine sulfate (Fisher Scientific #0219472905). The infection mix was removed on the 
following day and cells were left to recover in fresh MEF media (DMEM HG Thermo Fisher 
Scientific #10569010 with 10% FBS Atlanta Biologicals #S11150, Glutamax Thermo Fisher 
Scientific #35050079 and PenStrep Thermo Fisher Scientific 15140163).  
2.5.4. Reprogramming 
Two days after infection, cells were re-plated for molecular analyses, colony picking and 
alkaline phosphatase (AP) staining. In each experiment, infected fibroblasts from the different 
genotypes were re-plated at multiple densities to allow for optimal reprogramming efficiency. For 
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wild type cells, 40-60K per well of a 24w dish routinely generated high numbers of iPS cell clones. 
Besides for wild type, 40-60K per well of a 24w dish was also optimal for the Bard1 point mutants, 
Brca1tr/+ (and all combination mutations with Smarcal1 or 53BP1); Brca1tr/tr, 53bp1-/- as well 
as the heterozygous or homozygous Smarcal1 and 53bp1 single mutants. The 3 genotypes- 
Brca1tr/tr; Brca1tr/tr, Smarcal1+/- and Brca1tr/tr, Smarcal1-/- were plated at 120-160K per well 
of a 24w dish since we observed very few or no iPS clones at the densities selected for wild type. 
The remaining Brca1tr/tr, 53bp1+/- genotype was re-plated at 90K/well of a 24w dish. The OSKM 
reprogramming factors were induced with 1ug/ml doxycycline (Sigma # D9891) in mouse 
embryonic stem (mES) cell media, consisting of Knockout DMEM (Life Technologies #10829-
018), supplemented with 15% Knockout Serum Replacement (Life Technologies #10828-028), 
Glutamax (Thermo Fisher Scientific #35050079), MEM NEAA (Life Technologies #11140050), 
PenStrep (Thermo Fisher Scientific 15140163), 2-mercaptoetahnol  (Life Technologies #21985-
023) and 10ng/ul LIF (eBioscience #34-8521-82). Transduction efficiency was determined on 
reprogramming day 3 by staining for Sox2 (Stemgent #09-0024). Cells were fixed on 
reprogramming day 19-20 and stained for alkaline phosphatase with the Vector Red detection kit 
(Vector Laboratories #SK-5100). Reprogramming efficiency was determined by considering the 
number of AP-positive colonies per number of infected cells at the optimal plating density for each 
genotype.  
2.5.5. Immunofluorescence and DNA fiber analysis 
 Detection of γH2AX, phospho RPA(S33) and 53bp1 was performed on reprogramming D5 
with the following antibodies Phospho-RPA2Ser33 (Invitrogen # PA5-39809), Phospho-Histone 
H2A.X Ser139 (Cell Signaling # 9718), 53BP1 Antibody H-300 (Santa Cruz #22760).  
DNA fiber analysis was carried out as described in Terret et al. 2009 [143]. Briefly, 
fibroblasts of different genotypes were incubated on reprogramming day 5 with 25uM CldU for 
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30min, washed 3 times with warm PBS and incubated with 125uM IdU for another 30min. Fork 
stalling was then induced by a 5h treatment with 2mM hydroxyurea (HU). Fibers were stretched 
on slides and stained with anti-BrdU/CldU (Biorad # OBT0030) and anti-BrdU/IdU (BD # 347580) 
antibodies. Imaging was performed with a 100x objective on an Olympus microscope and fiber 
length was measured with Olympus cellSens imaging and analysis software. In an alternative fiber 
assay, fork stalling was induced by treatment with 2uM pyridostatin (PDS) during the 30min 
incubation with 125uM IdU.  
 
2.5.6. HR Assay 
 The HR competence of the different genotypes was evaluated in mouse induced pluripotent 
stem (iPS) cells with a CRISPR/Cas9-based assay where a zsGReen repair template is targeted to 
the Hsp90 genomic locus. This strategy has been described in detail by Mateos-Gomez et al. [129]. 
In short, 1x106 exponentially growing iPS cells were transfected with 200ng Cas9-puromycin 
vector and 800ng zsGreen repair template with Jetprimer transfection reagent (VWR #89129-922) 
as outlined in the manufacturer’s instructions. To enrich for Cas9-transfected cells, the plates were 
treated with 1ug/ml puromycin (Thermo Fisher #A11138-03) 20h post transfection for 12h. Three 
days after selection, HR was measured by flow cytometry for zsGreen.  
Proliferation and apoptosis  
  To evaluate proliferation, infected fibroblasts on reprogramming D2 were incubated with 
5uM Cell Trace CSFE proliferation dye (Thermo Fisher # C34554) for 20min at 37C as outlined 
in the manufacturer’s protocol. Cells were then changed to fresh mouse ES cell media, composed 
of Knockout DMEM (Life Technologies #10829-018), 15% Knockout Serum Replacement (Life 
Technologies #10828-028), Glutamax (Thermo Fisher Scientific #35050079), MEM NEAA (Life 
Technologies #11140050), PenStrep (Thermo Fisher Scientific 15140163), 2-mercaptoetahnol 
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(Life Technologies #21985-023) and 10ng/ul LIF (eBioscience #34-8521-82), supplemented with 
1ug/ml doxycycline (Sigma # D9891). Three days post incubation with CSFE (reprogramming day 
5) cells were harvested for flow cytometry.  
 For apoptosis analysis, cells were collected on reprogramming day 5 and stained without 
fixation with the Annexin V-FITC apoptosis detection kit (Sigma # APOAF-20TST) according to 
protocols provided by the manufacturer. The numbers of early and late apoptotic cells were 
determined by flow cytometry for Annexin V-FITC and propidium iodide (PI). Early apoptosis is 




















CHAPTER 3: DETECTION OF BASE ANALOGS INCORPORATED 
DURING DNA REPLICATION BY NANOPORE SEQUENCING 
 
3.1. MOLECULAR METHODS AVAILABLE FOR THE STUDY OF DNA 
REPLICATION 
The study on the role of BRCA1 in reprogramming to pluripotency used a widely employed 
DNA fiber assay to evaluate the protection of stalled replication forks. A significant shortcoming 
of this method is that the genomic location of stalling is not known. The variability in replication 
tract length on different fibers demonstrates that replication fork progression and stability are not 
equal across the genome. Mutations in double strand break repair pathways may have differential 
effects on different genomic areas and thereby contribute to genetic abnormalities in 
reprogramming and cancer. To address this, we started the development of a novel method for the 
analysis of replication progression, which can be used to study DNA replication and repair in 
various biological contexts. 
3.2. ABSTRACT  
DNA synthesis is a fundamental requirement for cell proliferation and DNA repair, but no 
tools exist to identify the location, direction and speed of replication forks with base pair 
resolution. Mammalian cells have the ability to incorporate thymidine analogs along with the 
natural A, T, G and C bases during DNA synthesis, which allows for labelling of replicating or 
repaired DNA. The Oxford Nanopore Technologies (ONT) MinION infers nucleotide identity 
from changes in the ionic current as DNA strands are pulled through nanopores and can 
differentiate noncanonical nucleotides from natural ones. Here, we demonstrate the use of the ONT 
MinION to detect 11 different thymidine analogs including CldU, BrdU, IdU, as well as, EdU 
alone or coupled to Biotin and other bulky adducts in synthetic DNA templates. We also show 
detection of IdU label, incorporated during DNA replication in the genome of mouse pluripotent 
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stem cells. We find that different modifications generate variable shifts in signals, providing a 
method of using analog combinations to identify the location and direction of DNA synthesis and 
repair at high resolution. We conclude that this novel method has the potential for genome-wide 
examination of DNA replication in stem cell differentiation or cell transformation.  
3.3. INTRODUCTION 
DNA replication is a fundamental requirement for the development of an organism and the 
life-long maintenance of organ function. An estimated 2-3x1011 cell divisions occur in the human 
body each day to replenish lost cells and repair tissue damage. While DNA is replicated just once 
during a cell cycle, the pattern by which this occurs varies between cell types [144], and is different 
in malignancy [145]. During the neural differentiation of mouse embryonic stem cells, for 
example, as much as 20% of the genome switches replication timing [146]. Mammalian 
development induces replication program changes which affect at least 50% of the genome [147]. 
The generation of induced pluripotent stem cells is associated with changes in replication timing 
which reset the replication pattern to resemble the one in embryonic stem cells [117]. Importantly, 
cancer cells acquire replication programs which differ from the ones in their normal counterparts. 
For instance, allelic replication asynchrony at the p53 and 21q22 loci has been described in 
invasive carcinomas [148]. Delayed replication of one allele of a tumor suppressor can interfere 
with gene expression and create a situation similar to loss of heterozygosity which is associated 
with malignancy [148]. Chromosome-wide delays in DNA replication have been shown to delay 
chromosome condensation and contribute to the chromosomal instability of various tumor cell 
lines [149]. Therefore, in addition to studying differential gene expression patterns, there is a 
strong rationale to study differences in DNA replication patterns in development and disease.  
Methods that are currently available to analyze the progression of DNA replication include 
a pulse of BrdU and immune-precipitation for labelled DNA [150]. Replication patterns can also 
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be inferred from the sequencing of Okazaki fragments [151] or from counting the number of reads 
in next generation sequencing data which allows the identification of early and late replicating 
regions as well as of replication origins [152]. However, next generation sequencing requires 
amplification during library preparation and averages the signal from different cells and DNA 
strands. To identify the progression of replication on a single DNA strand, a commonly used 
technique is DNA combing, which relies on sequential pulses with two modified nucleotides- IdU 
and CldU, fiber stretching on glass slides and staining with specific antibodies. While this 
technique can track replisome progression, stalling and restart in a genome-wide manner, it does 
not provide any sequence information. To study replication dynamics at a locus of interest, fiber 
analysis requires combination with fluorescent in situ hybridization [153]. This method, however, 
is very laborious and not scalable to the level of a complete eukaryotic genome. Thus, to the best 
of our knowledge, there is currently no technique that can capture location, direction and speed of 
replication fork progression on single molecules at a genome-wide level with high resolution.  
Nanopore technology has recently emerged as a powerful third-generation sequencing 
technique, primarily utilized for genome assembly due to its ability to produce ultra-long reads 
[154]. The system uses electrophoresis to transport DNA through a collection of nanopores and 
bases are identified by measuring changes in the electric current across the surface of the orifice 
[155] (Fig.18). In reality, signal shift is produced not by a single base, but is influenced by 5-6 
neighboring nucleotides, making contact with the pore and termed a k-mer.  Computational 
algorithms are then used to process the signal and determine the identity of the bases passing 
through. Since the nanopore platform does not require DNA amplification for library preparation, 
it can sequence cellular DNA directly and thereby avoid averaging signals from different DNA 
strands. Because nanopore technology does not rely on base-pairing to determine DNA sequence, 
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it may be used to distinguish not only the four canonical nucleotides (A, T, G, C), but potentially 
other types of base. Indeed, the system is able to detect methylated bases [156], which suggests 
that the sequencing of nucleotide analogs incorporated during DNA replication may also be 
possible. 
Here, we present the use of nanopore sequencing on the Oxford Nanopore Technologies 
(ONT) MinION to detect thymidine analogs that can be directly incorporated during DNA 
replication or generated in click cycloaddition reactions. Using a series of templates, we show that 
the MinION can distinguish between thymidine and all 11 analogs, with the greatest signal to noise 
ratio shown by IdU, CldU and Biotin-dU. We also show detection of IdU in substituted mammalian 
DNA. The methods presented in this study provide a path towards extracting comprehensive, 
genome-wide information on the origin, direction and progression of polymerases during DNA 
replication and repair from MinION sequencing reads.  
Figure 18. An artist's representation of nanopore sequencing. 
A DNA helicase at the pore unwinds dsDNA. Single DNA strands pass through the pore (CsgG 
from E. coli in this illustration) while an electrical current is applied across the pore membrane. 
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Changes in the current as ssDNA passes through are recorded and used in computational 



































3.4.1. DETECTION OF SINGLE-BASE DNA MODIFICATIONS WITH NANOPORE 
SEQUENCING  
To determine the ability of the ONT MinION sequencer to detect modified bases, we 
designed synthetic templates containing a single modification in a defined location. Template 
assembly involved a vector nicking step with endonuclease nb.BbvCI which generated a 63bp 
region of ssDNA on the minus strand, followed by the ligation of an oligo with one modified 
thymidine base (Fig.19A). This approach to replace segments within a plasmid with a labelled 
oligo has previously been used for FRET studies and reported to result in >75% substitution [157]. 
We used oligos without modification, or containing 5 different modifications, EdU, CldU, BrdU, 
IdU, or Biotin for the substitution reaction (Fig.19B). Also, we modified EdU with a series of 
compounds of increasing molecular weight: azide, nicotine, glucose, AF488, AF647 and a 10bp 
single stranded DNA oligo through click cycloaddition reaction [158]. This method allows the 
attachment of any azide group containing moiety to alkyne-substituted DNA and has been reported 
to be nearly 100% efficient [159]. Dot blots for AF647, AF488, BrdU and Biotin modified 
plasmids showed efficient labelling (Fig.19C). Following the replace reaction, the vector was 
linearized with SpeI to generate a 6184-bp double-stranded training template with one modified 
thymidine on the minus strand at position 3073, which was sequenced on the MinION (Fig.19D).   
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Figure 19. Design and assembly of training 
templates with single modifications. 
Design and assembly of training templates with single 
modifications. A). A schematic of the two-step 
assembly of single modification training templates. The 
first step is nicking with the restriction enzyme 
nb.BbvCI and the second-ligation of a ssDNA oligo 
which carries a modification. The vector is then 
linearized with SpeI to generate a 6184bp sequence 



















Figure 19. (continued) B). Sequence of the single modification oligos used for ligation. C). Dot 
blots with ligation products for AF647, AF488, BrdU, IdU and Biotin modifications, 




Figure 19. (continued) D). A schematic illustrating the sequencing of a training template with a 












To identify modified nucleotides, we developed NanoMod, an analysis tool which calls 
DNA modifications directly from electrical signals [160]. NanoMod uses Albacore for base calling 
and performs indel error correction by aligning signals to a reference sequence. The input to 
NanoMod is a dataset with two groups of samples-a modified template and a sequence-matched 
control, while the output is the ranked list of regions with modifications. Signals from control and 
substituted samples are then compared using two statistical assays-Komogorov-Smirnov test and 
Stouffer’s method for calculating combined p values. We used NanoMod to score individual 
nucleotides in 5-bp sliding windows to detect the presence of thymidine analogs. All 11 
modifications (Fig.20A) in the dataset caused signal shifts at base 3073 as well as at neighboring 
positions (Fig.20B-M). The analogs EdU, CldU, BrdU and IdU caused signal shifts spreading as 
far as 3-4 bases upstream and 2 bases downstream of the modified position (Fig.20B, C, D, F), 
consistent with the minion detecting signals from a 5-6 bp k-mer. Therefore, the signal of the 
modified T is present in neighboring bases. The magnitude of the signal change was proportional 
to the size of the moiety with one of the largest unclicked analogs IdU (MW=354.1g/mol) 
generating the most significant change in pore current, log(Combined p-value) = -175 (Fig. 20F). 
The smallest modification, EdU (MW=252.23 g/mol) was detectable as well at log(Combined p-
value) = -125 (Fig.20A). A highly significant change in signal at 3073 was also recorded for the 
bulkier analog- Biotin, with a log(Combined p-value)=-150 (Fig.20I). Purification of the plasmid 
after the replace reaction with streptavidin beads, followed by sequencing further increased the 
significance of the change, with a log(Combined p-value)= -250 (Fig.20J). Therefore, modification 
at 75% [157], was sufficient to call the modified base, while 100% modification further magnified 
signal change. Biotin influenced electrical signals further away from the modification than EdU, 
CldU, BrdU or IdU. An increased number of surrounding bases affected-as many as 3-4 
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nucleotides upstream and about 10 downstream of the modified position (Fig.20I, J) indicates that 
the effect of bulky modifications can spread beyond a single k-mer.  
We also compared modifications attached to the training template by click cycloaddition - 
an azide, nicotine, glucose, AF488 and AF647. In regions outside the modified base, we did not 
observe significant changes in signals, indicating that the click reaction did not affect the ability 
to sequence DNA on the MinION (e.g. compare position T3063 and T3083 on the control and 
experimental templates in Fig.20G). At the modified base, nicotine showed a significant change 
with a log(Combined p-value) = -74 (Fig.20G). The mean raw signal of bulky bases caused a wider 
spread in signal, which generally affected 5-6 bases preceding the modification and about 2-4 
bases downstream (Fig.20E, G, H). Clicked moieties AF488 and AF647 caused a more extensive 
downstream current shift, spreading as far as 8-10 bases beyond the modified position (Fig.20K, 
L). The mean raw signal at the modified base was visibly different when compared to control, 
though the change did not translate into lower p-values in the NanoMod statistical analysis. The 
largest clicked modification - a ssDNA oligo, expected to generate a branched structure, caused 
the smallest change in signal which spread over 10 bases upstream and 2-3 positions downstream 
of 3073 (Fig.20M). In this particular case, reduced progression through the pore, or signal 
integration from bases on the training template and the clicked oligo might have contributed to the 
low shift in current recorded for the modified position.  
These observations point to a relationship between adduct size and the magnitude of signal 
shift at the modified position as well as the neighboring bases. In general, bulkier moieties caused 
more pronounced changes in the raw signal at the modified position, and affected more bases in 
its vicinity. The differences in signal spread between adducts of different molecular weight show 
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that pairs of analogs, such as IdU and Biotin, can be distinguished from each other based on the 
width of the window affected by nanopore current shifts (Fig.20F and Fig.20J).  
 
Figure 20. Detecting a series of single-base modifications with increasing molecular weight 
through MinION sequencing. 








Figure 20. (continued). A violin plot of the known modification site and the surrounding bases 







Figure 20. (continued). A violin plot of the known modification site and the surrounding bases 







Figure 20. (continued). A violin plot of the known modification site and the surrounding bases 







Figure 20. (continued).  A violin plot of the known modification site and the surrounding bases 
for K). AF488, L). AF647 and M). a 10bp ssDNA oligo, attached to position 3073 by click 
cycloaddition. In each panel, the first line denotes position, followed by the base, the second line 
shows mean raw signal from the control and modified sample, the third line contains the p-value 
(pv for short) for a Kolmogorov-Smirnov test, and the fourth line displays the combined p-value, 
calculated using Stouffer’s method. ‘DS 1’ in blue represents the non-modified oligo samples, 
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while ‘DS 2’in green stands for the sample with a modification at position 3073. ‘- strand’ denotes 
































3.4.2. DETECTION OF MULTIPLE DNA MODIFICATIONS WITH NANOPORE 
SEQUENCING  
To mimic the scenario of pulsing replicating cells with nucleotide analogs, which are 
incorporated at multiple positions into newly synthetized DNA, we repaired the nb.BbvCI nicks 
on the minus strand of the training sequence by ligating an oligo with 14 thymidine modifications 
between positions 3042 and 3104 (Fig. 21A). Based on the results with a single defined position, 
we selected 4 analogs - EdU, CldU, IdU, and Biotin added to EdU by click cyclo-addition (Fig. 
21B). Efficient replacement was confirmed by dot blots for CldU, IdU and clicked Biotin (Fig. 
21C). Templates with replacements were sequenced and analysis was carried out by dividing the 
reference sequence into ~400 regions of 60bp each with a 30-bp overlap between adjacent 
windows. For all analogs tested, NanoMod correctly identified the modified region between 3042 
and 3104 as shown by the p-values for Kolmogorov-Smirnov test and Stouffer’s method (Fig.22A-
C). The most significant shift of signal was centered around a modified base, gradually abated with 
increasing distance from the analog and raised again in the vicinity of the next modification on the 
template. Within each template, some modified thymidines generated stronger signals than others 
(Fig.22A-C). As in templates with single modifications, the magnitude of signal shift in sequences 
with multiple analogs was determined by the size of the adducts with IdU generating the greatest 
signal to noise ratio (Fig.22C). Biotin, the largest moiety, caused signal changes spreading over 
the whole region between 3042 and 3104. This spread of signal is likely related to the chemical 
structure of biotin, and the ability of bulky adducts to influence the current reading beyond a single 
k-mer. This dataset on multiple modifications demonstrates that MinION sequencing and analysis 





Figure 21. Design and assembly of training templates 
with multiple modifications. 
A). A schematic of the strategy used to assemble training 
templates with multiple modifications. A ssDNA oligo 




















Figure 21. (continued) B). Sequence of the multiple modification oligos used for ligation. E = 
EdU; Cl = CldU and I = IdU. C). Dot blots with ligation products for CldU, IdU and Biotin. CldU 
and IdU were visualized by antibody staining on the blot. Biotin was seen after incubation with 




Figure 21. (continued) D). An illustration of sequencing a DNA template with multiple analogs 
















Figure 22. Detection of multiple modifications with MinION sequencing. 








Figure 22. (continued) B). A violin plot of the modified region 3042-3104 and surrounding bases 










Figure 22. (continued) C). A violin plot of the modified region 3042-3104 and surrounding bases 
for IdU. ‘DS 1’ in blue represents the non-modified oligo sample, while ‘DS 2’ in green stands for 
the multi modified template. The Kolmogorov-Smirnov test p-value is shown on line 3, while the 
combined p-value, calculated by Stouffer’s method is displayed in line 4. Red stars indicate the 




3.4.3. A COMPARATIVE ANALYSIS OF NUCLEOTIDE ANALOGS FOR gDNA 
MODIFICATIONS  
To determine if pore sequencing and the analysis method NanoMod developed here can be 
applied to sequencing base analogs incorporated by replicating cells in genomic DNA, we 
performed computational simulations. We first determined the level of analog substitution in vivo 
by exposing primary human fibroblasts to EdU for 24h, or a complete cell cycle. Purified, EdU-
containing genomic DNA was then labelled with AF647 in a click cycloaddition reaction and the 
level of EdU-AF647 substitution was determined by measuring sample fluorescence against a 
standard curve of PCR products with known percentage substitutions of EdU, clicked with AF647. 
This analysis revealed that 20% of thymidine bases in genomic DNA were substituted with EdU 






Figure 23. Substitution of mammalian genomic DNA with EdU.    
A). Dot blots with EdU-substituted genomic DNA clicked with A647-azide. B). A647-
fluorescence measurement of EdU-substituted DNA. The standard curve was prepared with 
products of PCR reactions ran with known concentrations of dTTP to dEdUTP and processed 
through click cycloaddition with A647 azide. The analysis shows ~20% substitution in genomic 





























Based on this result, we performed computational simulations with 20% modified and 80% 
unmodified reads to determine what coverage would be required to detect single (Fig.24A) and 
multiple (Fig.24B) modifications in genomic DNA. Since the fraction of modified reads without 
purification is approximately 75% [157], the proportion of modified reads in the simulation is 
approximately 15%. IdU and CldU were easiest to detect in the group of analogs that can be 
directly incorporated during DNA synthesis, requiring 450 reads of a modified site to rank strands 
with a single modification in the 0.05 percentile or less (Fig.24A). The calling of BrdU, CldU and 
the calling of single EdU-modified strands also obtained the highest 0.05 percentile rank as low as 
450 or 950. Similarly, Biotin modifications were ranked in the 0.05 percentile range with only 450 
reads. The clicked analogs-an azide group, nicotine and glucose required 950 reads, almost twice 
the number noted for IdU and CldU, to achieve the 0.05 percentile rank. The clicked fluorophores 
AF488 and AF647 required more extensive coverage-1950 and 2450 reads, respectively for more 
than 75% of the strands to be ranked in the 0.05 percentile or between percentiles 0.05 and 0.12. 
This result is consistent with the wide-spread signals of lower significance described for AF488, 
AF647 and the ssDNA oligo in Fig.20. This result corroborates the observation that thymidine 
analogs of higher molecular weight IdU, and Biotin are readily detected on the MinION platform.  
To determine the number of reads required to identify a region with multiple modifications, 
we performed the same simulation with 14 thymidine analogs in a single template (Fig.24B). 
Multiple EdU modifications required 250 reads for reliable detection (percentile 0.05 or between 
the 0.05 and 0.12 percentiles). For other analogs CldU and IdU, only 100 reads proved enough for 
correct calling (percentile 0.05 or between the 0.05 and 0.12 percentiles). The template which 
contained multiple clicked biotins required 350 reads for accurate detection. This analysis showed 
that the presence of multiple modified bases in a DNA segment facilitates detection with 
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NanoMod, requiring a smaller number of reads compared to a single modification. IdU was the 
modification that was most readily detectable in both the modelling of single modifications and 




Figure 24. Sequencing depth required for the calling of base analogs in mixed samples with 
unmodified and modified reads. 
A). Modeling using single modified base templates. The X axis represents the number of reads 
used for the analysis, and the Y axis shows the fraction a modified site can be ranked by percentile 






Figure 24. (continued) B). Modeling using templates with multiple modifications for the modified 
region between 3042 and 3104 with tracks of thymidine analogs. IdU and CldU modifications 












3.4.4. THYMIDINE ANALOGS INCORPORATED IN REPLICATING MAMMALIAN DNA 
CAN BE DETECTED ON SINGLE STRANDS.  
To test if the MinION platform in conjunction with NanoMod can detect nucleotide analogs 
incorporated in replicating DNA, we incubated mouse embryonic stem (ES) cells from a pure 
C57BL/6J strain with 25uM IdU for 24h. Genomic DNA from unlabelled and IdU-incubated 
samples was then harvested, sheared in 6-8kb fragments and prepared for 1D sequencing on the 
MinION system. Error correction and signal annotation were performed with NanoMod. Base 
calling was accomplished with Albacore v2.3.1 and long reads were aligned with the GRCm38 
(mm10) mouse reference genome. We aligned all reads from the IdU sample to the mouse 
reference genome and used a set of IdU-covered reads and control reads in the subsequent analysis. 
These reads were from different, rather than the same genomic location. Reads were split in 9-
mers with no thymidines (VVVVVVVVV), V=AGC, 1 thymidine in the center of the k-mer 
(VVVVTVVVV) or 2 and more thymidines at different positions on the plus strand of the k-mer. 
This classification included 335 non-T k-mers and 668 T-containing k-mers of different sequence 
composition with coverage of >500 reads per k-mer. Current signals were collected from the 
central T as well as 2 nucleotides upstream and 2 downstream of the base and used in a 
Kolmogorov-Smirnov test to calculate p-values. Stouffer’s method was then applied to calculate a 
combined p-value for each 9-mer. The procedure was repeated 50 times and the median of the 
resulting 50 p-values was plotted on a logarithmic scale. Comparing IdU labelled samples with 
unlabelled controls revealed that 20% of the T-containing k-mers in the IdU sample had combined 
log10 p-values between -308 and -10, while none of the non-T k-mers had a p-value in this range, 
showing that IdU substitution in T-containing k-mers generates a detectable signal shift (Fig.25A, 
B). Comparison of k-mers containing either 1T or 2T resulted in greater significance of detected 
differences: 25% of 1T and almost 40% of 2T-contaning 9-mers had combined log10 p-values 
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between -308 and -3 (Fig.25C, D). Analysing k-mers with p-values below 10-7 showed that only 
1.3% of non-T k-mers have p-values in this range, while 5.9% of the 1T, 24.8% of the 2T and 68% 
of the 3T containing k-mers had signals with p-values <10-7 (Fig.25E). This result demonstrates 
that the method employed here has low background and can detect incremental signal differences 
generated by the presence of increasing numbers of IdU-substituted thymidines. To determine 
whether signals from a k-mer of a specific sequence could be used to distinguish IdU from 
thymidine, two selected 9-mers GAGATACAC and GAGTTACAC were divided into 5 different 
k-mers. Electrical signals from control and IdU labelled samples of the same k-mer were plotted 
and compared using NanoMod. A significant shift was seen in the IdU containing k-mers, with the 
shift depending on the position of the T within the k-mer (Fig.25F,G). This analysis used 
427IdU/229control reads for GAGATACAC and 310IdU/211control for GAGTTACAC to 
identify an IdU containing k-mer in cellular DNA. This analysis shows that thymidine analogs, 
incorporated by replicating mammalian cells, can be called with nanopore sequencing, and that T 
containing k-mers of the same sequence, from different locations of the genome can be combined 
for the calling of base modifications. The combination of approximately 200 different k-mers on 
a single read should provide a tool to identify replicated DNA from long nanopore reads.  
To determine if we can detect single IdU-substituted DNA molecules with Nanomod, we 
randomly selected 70% of the reads with T-containing k-mers from different genomic locations in 
the control genomic DNA sample. We calculated the signal mean and standard deviation for the 
central 5 bases (central T as well as 2 bases upstream and 2 bases downstream) of each 9-mer. 
These results were used to calculate a combined p-value for each T in the remaining 30% of the 
T-containing k-mers in the control genomic DNA sample and the IdU-substituted sample with the 
following thresholds for read length: 500, 800, 1000, 1500, and 2000bp. This analysis showed that 
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IdU-substituted single reads of length 0.8-1.0kb can be detected with Nanomod in the 10% quantile 
and individual modified reads of 1.0-1.5kb could be called in the 15% quantile (Fig.25H). These 
results demonstrate that IdU, incorporated in newly-synthesized mammalian DNA can be detected 
on individual DNA molecules with MiniION sequencing and Nanomod analysis.  
 
Figure 25. Detection of IdU incorporated into replicating mammalian DNA. 
A). Combined p-values calculated with Stouffer’s method for non-T containing 9-mers. The 
combined p-value includes p-values for the central base of the 9-mer as well as 2 bases upstream 
and downstream. B). Combined p-values for T-containing k-mers. All T-containing 9-mers were 










Figure 25. (continued) C). Combined p-values for 1T-contaning k-mers. This analysis included 
9-mers with the thymidine base in the middle. D). Combined p-values for 2T-containg k-mers. The 
first T was set to the middle of the 9-mer and the other T could take any other possible position. 
 
Figure 25. (continued) E). Pie chart showing the percentage of 9-mers with p-values less than 









Figure 25. (continued) F). Signals changes as a selected 9-mer from IdU-substituted genomic 
DNA with the sequence GAGATACAC, and G). GAGTTACAC was separated in 5 different k-











Figure 25. (continued) H). Detection of single modified reads. The top panel contains ranges of 
read lengths. The purple stars indicate the read length required for the detection of individual IdU-
substituted genomic DNA reads when integrating signals from k-mers with p-values in the 10% 





















Analysis of DNA replication at a single molecule level and genome would greatly increase 
our understanding of DNA replication and genetic stability in development and disease. Towards 
this aim, we show here that pore sequencing with the MinION can be used in conjunction with 
NanoMod to detect a panel of thymidine modifications in synthetic templates, as well as, IdU 
incorporated in the DNA of replicating mammalian cells. Compounds, which are chemically alike, 
but with different molecular weights or different structure, can generate distinct signals in a pore 
[162]. Here we present increased signal change with increasing molecular weight from EdU, CldU 
and BrdU to IdU with a signal spread, affecting 2-4 neighboring bases on each side of the analog. 
Structurally bulkier moieties of high molecular weight, such as biotin, generated large signal shifts 
spreading as far as 10 nucleotides in the neighborhood of the modified base. Larger polymers have 
been reported to have increased pore residence times compared to shorter molecules [163] and 
thus the extensive signal spread with biotin modified DNA may be due to longer dwell times in 
the pore.  
In this work, we also demonstrate that click cycloaddition reactions can be used to generate 
any desired chemical change after incorporation of a nucleotide with a reactive group. These 
analogs could be detected without further modification, and the clicking of bulky adducts again 
showed a wider spread in signals. Though click chemistry using copper catalysts can introduce 
DNA damage, novel copper-free click chemistry is now available and will likely be more suitable 
for this application [164]. For example, AmdU is an azide group-containing analog, which is 
incorporated during DNA replication and reacts with alkynes in copper-free reactions, allowing 
the formation of a bulky adduct while protecting DNA from damage [165, 166]. A base with a 
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vinyl-group, such as VdU, also allows the introduction of further modifications via copper-free 
alkene-tetrazine ligation[167].  
The difference in signal spread between small analogs and larger bulky adducts can be 
potentially leveraged to distinguish between a small and a bulky analog which opens up the 
possibility of using the platform to determine replication patterns. For example, studies on the 
progression of DNA replication may use the sequential application of two analogs, such as IdU 
and EdU with the intent to modify the latter further with biotin and form a larger base. This advance 
will require the development of new algorithms which can distinguish one analog from the other 
as this is not yet possible with the methods used in the current study. The use of two analogs is 
routinely applied in studies of fork stalling, origin mapping, analysis of replisome speed and 
direction. The ability to add information on location in the genome on single DNA strands through 
pore sequencing would greatly facilitate our understanding of the pattern of DNA synthesis in 
normal and abnormal cells. To this end, we provide a proof of principle that noncanonical bases 
that can be incorporated into cells during DNA replication can be detected with nanopore 
sequencing. We chose IdU for analysis, as it performed best in modeling to detect a modified 
nucleotide when 20% of T’s are substituted. Using IdU labelling through a complete cell cycle, 
we demonstrate that IdU-substituted mammalian genomic DNA, can be distinguished from control 
DNA. A coverage of 200-300 reads per 9-mer was sufficient to observe significant differences. As 
these k-mers are from different locations of the genome, k-mers from the same read may be 
combined for the analysis of a labelled DNA strand, thereby amplifying the signal and reducing 
the coverage requirement. We used this strategy to detect IdU-substitutions on individual DNA 
molecules and showed that single IdU-containing reads of 0.8-1.0kb can be called with Nanomod 
when sampling from the top 10% lowest p-values of T-containing k-mers along the read. This 
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result is a significant step forward in the development of applications to study origin usage, 
replisome direction and stalling, as well as, DNA repair. The feasibility of using nanopore 
sequencing for such purposes was recently demonstrated by a study which maps origin usage and 
fork direction in yeast with D-NAscent sequencing [168].  
The MinION has been successfully used for the assembly of eukaryotic genomes, such as, 
yeast [169], C-elegans [170] and recently the human genome with a median coverage of 26x, using 
43 flow cells [171]. This demonstrates that nanopore sequencing can be used to analyse a 
mammalian genome.  Furthermore, the PromethION, a high throughput MinION platform can run 
48 flow cells simultaneously and generate up to 7.6Tb data during a 72h run. Applying single read 
analysis on PromethION data will allow the assembly of detailed replication dynamics maps, 
which inform on origin usage and fork progression on single DNA strands. This is currently not 
possible with existing methods, which require amplification, resulting in population averages. 
Therefore, sequencing DNA replication using nanopores, termed here Replipore sequencing, is a 
novel technology with significant potential in research and diagnostics.  
Cell proliferation plays an important role in many diseases. Abnormalities in DNA 
replication can result in genome instability, cellular senescence or apoptosis, and are therefore 
highly relevant to regenerative medicine. Furthermore, DNA replication is cell type specific and 
dependent on epigenetic principles that also regulate cell type specific gene expression. Due to the 
fundamental requirement of DNA replication in cell cycle progression, the cell type specificity of 
the replication program may have an important role in determining limitations in cell proliferation 
[172]. Thus, insights about polymerase progression derived from sequencing modified nucleotides 
through nanopores will likely prove instrumental to our understanding, diagnosis and ultimately 
treatment of diseases characterized by cell cycle abnormalities.  
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3.6. MATERIALS AND METHODS 
3.6.1. Training Template Assembly 
 For training sequence assembly, the pCALNL-GFP vector (Addgene plasmid#13770) was 
digested with AgeI and NotI to release the E-GFP insert. A double stranded DNA oligomer with 
5 nbBbvCI sites was prepared by hybridizing two single-stranded DNA oligos and ligated into the 
purified empty vector as described in Luzzietti et al.[157]. The product was transformed into E-
coli. Nicking and substitution reactions were performed as outlined in [157] with oligos, purchased 
from Baseclick, Germany. Prior to MinION library prep, all templates were linearized with SpeI 
(New England Biolabs).  








Substitute Oligo Single: 
5’PhosTGAGGCTACAATCTGCTGAGGTCATCTGAGCXGAGGACAATTGACGCTGAGG
TCGTGGCAAGC-3’ X = EdU, CldU, BrdU, IdU 
 
Substitute Oligo Multi: 
5’PhosXGAGGCXACAAXCXGAGGXCAXCXGAGCXGAGGACAAXXGACGCXGAGGX
CGXGGCAAGC-3’ X = EdU, CldU, IdU 
 
3.6.2. Click Cycloaddition Reactions 
 Click cyclo-addition was performed on single stranded EdU replace oligos prior to the 
substitution reaction. Briefly, 1ug phosphorylated oligo was incubated with reagents from the 
CuAAC Biomolecule Reaction Buffer kit (Jena Bioscience CLK-072) and 250uM azide for 1h at 
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37C. Separate reactions were carried out with the following azides: sodium azide (Sigma S2002), 
Nicotinoyl azide (Sigma CDS006775), 6-azido-6-deoxy-D-glucose (Sigma 712760) Biotin azide 
(Thermo Fisher B10184), AF488 azide (Thermo Fisher A10266), AF647 azide (Thermo Fisher 
A10277), and a ssDNA oligo purchased from Integrated DNA Technologies: 5’-
GGATAGCCTC/3AzideN/-3’. All click products were purified by precipitation.  
3.6.3. Dot Blots 
 For dot blots, 100-200ng DNA was denatured with 20mM NaOH for 5min at 99C, cooled 
on ice and neutralized with 0.6M ammonium acetate. Spotting was performed manually on a 
0.45uM nylon membrane (Thermo Fisher 77016). Once fully dried, the membrane was baked in a 
microwave for 2.5min. Prior to imaging, Biotin-containing blots were stained with A647-
Streptavidin (Thermo Fisher S32357). For this procedure, the baked membrane was incubated with 
3% BSA in TBST for 15min, followed by A647 Streptavidin 1:500 (Thermo Fisher S32357) for 
45min at room temperature and 3 washes with TBST. To detect CldU or IdU-containing DNA, 
500ng-1ug of sample was spotted on the membrane and stained with rat BrdU/CldU 1:500 (Bio 
Rad OBT0030S) or mouse BrdU/IdU 1:500 (BD 347580) in 3% BSA in TBST for 1h at room 
temperature. Staining with mouse ssDNA antibody 1:500 (Millipore MAB3034) was used as a 
loading control. To visualize the signal, the membrane was incubated with Alexa Fluor 647 and 
Alexa Fluro 488 secondary antibodies at 1:500. Following washes, the membranes were imaged 
with a Biorad ChemiDoc MP Imaging System. 
3.6.4. MinION Runs on Synthetic Templates 
All samples were sequenced on MinION R9 flow cells. Sequencing libraries were prepared 
with Ligation Sequencing Kit 1D (ONT SQK-LSK108), following manufacturer’s instructions. 
Each run was performed with 250-500 ng purified DNA. Typically, a single flow cell was used for 
multiple samples with washes in between, carried out with the Flow Cell Wash Kit (ONT EXP-
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WSH002). Fast5 data files from each run were analyzed with NanoMod as outlined in Liu et. al 
[160]. 
3.6.5. MinION Runs with Genomic DNA 
 For genomic DNA runs, mouse embryonic stem cells from a pure C57BL/6J strain 
(Jackson LAB Strain # 000664) were incubated with 25uM IdU for 24h. Cells were then harvested 
and genomic DNA was extracted with a High Pure PCR Template Preparation Kit (Roche 
11796828001). MinION runs were performed on R9 with 400-500ng purified DNA per sample 
following library preparation with Ligation Sequencing Kit 1D (ONT SQK-LSK108). For each 
run, unlabelled DNA was loaded first and sequenced for 5-6 hours. This was followed by a wash 
step with the ONT wash kit (ONT EXP-WSH002), priming and loading of IdU-substituted gDNA 
which was run until the flow cell expired, typically from 8 to 20 hours without voltage adjustments. 
Analysis was performed with data from two combined runs. The combined control data set 
included 719,295 long reads covering ~2.4G bases while the IdU sample was represented by 













CHAPTER 4: FUTURE DIRECTIONS AND PERSPECTIVES 
 
4.1. BRCA1 IN REPROGRAMMING TO PLURIPOTENCY 
 The current study shows that BRCA1 is required for reprogramming to repair replication-
associated DNA damage by homologous recombination. Interestingly, eliminating 53bp1 makes 
iPS cell generation more efficient, due to the absence of competition between 53bp1 mediated 
NHEJ and Brca1-dependent HDR for one-ended DNA breaks.  
To rule out the possibility that ablation of 53bp1 interferes with the transcriptional activity 
of p53 and improves reprogramming by preventing apoptosis [92], we are looking into p21, Bax 
and Bbc3/Puma induction in wild type and 53bp1-/- cells post irradiation. Our preliminary data 
shows comparable upregulation of p21 transcript in wild type, 53bp1+/- and 53bp1-/- cells, which 
shows that 53bp1 does not improve reprogramming efficiency by compromising p53 dependent 
transcription. 
To further strengthen the finding that DNA repair pathway choice is a critical determinant 
of reprogramming efficiency, we are in the process of stimulating HDR during reprogramming by 
overexpression of Rad51. We are also determining the homologous recombination efficiency in 
heterozygous 53bp1 knockout cells. These results aim to establish a correlation between 
homologous recombination efficiency and reprogramming efficiency. 
To confirm that the breaks which limit reprogramming efficiency are one-ended, we have 
begun experiments where cells of wild type and 53bp1-/- genotypes are irradiated to induce two-
ended DSBs or treated with the topoisomerase 1 inhibitor camptothecin (CPT), which generates 
one-ended DSBs. Our preliminary observations show that 53bp1-/- cells undergoing 
reprogramming are less sensitive to CTP, compared to wild type controls.  
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Our data points to one-ended DSBs in late S/G2 as the main limitation to reprogramming. 
To confirm that the most consequential damage is indeed in late S/G2, we are preparing cell cycle 
profiles of wild type and Brca1-deficient cells to determine where in the cell cycle these genotypes 
arrest. In addition, we have derived iPS cell lines from wild type, Brca1tr/tr as well as Brca1tr/tr, 
53bp1-/- genotypes, which we have sequenced on the Bionano Genomics platform to determine 
which regions of the genome are lost during reprogramming. To capture reprogramming-induced 
copy number variation, we have included two sibling iPS cell clones from the same somatic cell 
culture for each genotype in the analysis. Our expectation is that Brca1-deficient iPS cells will 
have copy number losses in late replicating regions, including in common fragile sites.  
Surprisingly, γH2AX marked DNA damage does not directly correlate with 
reprogramming efficiency. As 53BP1 is an important factor in reprogramming, we are currently 
looking at γH2AX and 53BP1 double positive foci in the context of HDR deficiency, SFP rescue 
and SFP deficiency. We expect that Brca1tr/tr, Smarcal1-/- cells accumulate 53BP1 foci in 
numbers similar to the Brca1tr/tr genotype, which results in poor reprogramming, despite 
restoration of SFP. We expect that 53BP1 foci are a better predictor of reprogramming efficiency 
than either γH2AX or phospho-RPA (S33). 
An intriguing interpretation of our findings is that the function of the genomic regions 
which are difficult to replicate is to form double strand breaks, which serve as a primary barrier to 
reprogramming. These one-ended double strand breaks act upstream of tumor suppressors p53, 
p21 and Rb, which limit reprogramming. Ablation of p53, p21 or Rb increases the efficiency of 
iPS cell generation. Equally, the deletion of unstable genomic regions reduces the signal upstream 




4.2. DETECTION OF MODIFIED NUCLEOTIDES WITH NANOPORE 
SEQUENCING 
 The main conclusion of this project is that thymidine analogs, incorporated into nascent 
DNA during replication or repair can be detected with nanopore sequencing. Importantly, besides 
calling of modifications on synthetic templates, we show detection of IdU in mammalian genomic 
DNA. This result has wide implications for the development of techniques which track replication 
fork stalling in a sequence-specific context. To bring the technology closer to this point, we are 
currently looking at synthetic templates with two different analogs in an attempt to distinguish 
them from each other.  
4.3. TYING GENETIC STABILITY TO CELL IDENTITY 
Replication of the DNA is a fundamental requirement for progression through the cell cycle 
and thereby for the development and maintenance of all tissues in the human body. Though all 
cells duplicate their DNA once before division, they do so in a manner dependent on cell type. 
Since replication tends to begin in regions with open chromatin and active genes, about half of the 
human genome is replicated in a cell type dependent temporal pattern, while the other half is cell 
type independent [144]. Surprisingly, a functional significance of cell type specific DNA 
replication has not been established because of fundamental experimental challenges. It is not yet 
possible to manipulate all cell type specific origins and ask whether a cell can still progress through 
the cell cycle. Various observations, including feedback between replication progression and 
origin activity [173] as well as checkpoints monitoring the completion of S-phase before entry into 
mitosis, suggest that DNA replication is well prepared to duplicate the genetic information of any 
cell type. According to this interpretation, differences in DNA replication patterns are a mere 
adaptation to epigenetic changes required to establish cell type specific gene expression. Hence, 
most research to better understand different cell states has focused on the processes governing 
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gene expression, while cell type specific DNA replication remains a little explored dimension of 
cellular biology.  
A connection between genomic stability and cellular identity is visible in various 
experimental systems. The conversion of somatic cells to induced pluripotent stem cells is 
associated with DNA damage and replication stress. In the absence of proteins involved in DNA 
damage repair, such as Brca1, Brca2 and Rad51, reprogramming fails [24]. Furthermore, cancer 
cells are widely known to duplicate their genetic material in an aberrant manner, often associated 
with DNA damage and genomic instability. The transfer of somatic nuclei to eggs leads to 
segregation errors related to problems with DNA replication [115]. Importantly, since early 
embryonic cells are the only cell type that does not require gene expression for cell cycle 
progression, nuclear transfer experiments conclusively show that cell type specific DNA 
replication provides constraints on the ability to progress through the cell cycle. Consequently, the 
pattern of DNA replication is not a mere adaption to a cell type specific gene expression program. 
Rather, it limits the number of possible cellular states compatible with genetic integrity during cell 
proliferation. The organization of the genome and the packaging of the DNA in chromatin 
determine the ability to replicate and also enables cell type specific gene expression patterns, 
providing a link between cell identity and genetic stability.  
The significance of this model to cellular biology is profound. The model predicts that cells 
with abnormal gene expression states will also have a compromised replication program, resulting 
in the activation of checkpoints that prevent or slow cell cycle progression (Fig.26). Thereby, 
checkpoints of genetic integrity are also the checkpoints of cellular identity, enabling continuous 
selection for cellular fitness in proliferating cells. During growth and development, this ensures 
the optimization of cell and organ function. During aging, it results in cell cycle arrest of damaged 
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cells. During terminal differentiation, the inactivation of a cell type specific replication program 
may be used in a physiological manner to permanently halt the proliferation of entire groups of 
cells. For instance, neurons do not proliferate, and forcing them into DNA replication results in 
cell death [174]. Cell type specific DNA replication may also be the primary impediment to the 
growth of cells assuming an abnormal identity. Consistent with this observation, DNA replication 
stress has been identified as an early barrier to tumorigenesis [175]. Proliferating cancer cells 
represent the rare gaps in this quality control system, allowing cell cycle progression of some 
abnormal cellular states, albeit with a compromised replication program and genetic instability. 
Most abnormal cell states are incompatible with DNA replication and cell cycle progression would 
result in lethal chromosomal abnormalities. Perhaps the most important implication of this model 
is that, if cell type specific DNA replication is a cellular mechanism preventing the proliferation 















Figure 26. Cell type specific DNA replication programs limit changes in cell identity. 
A). Proliferating cells blue panel: Cell type transitions during normal development follow along 
cell type specific replication programs. In contrast, forced changes in cell identity during 
reprogramming to pluripotency (e.g. fibroblast to iPS cell) or direct conversion to another cell type 
(e.g., fibroblast to hepatocyte) undermine replication program integrity and activate cell cycle 
checkpoints. Our current studies suggest that the consequences of compromised DNA replication 
program are one-ended DSBs that require repair by homologous recombination. Inefficient repair 






Figure 26. (continued) B). Proliferating cells pink panel: Deviation from a cell type specific 
replication program compatible with genetic stability (referred to as ‘replication ground state’) 
occurs during cell transformation. The outcome may be cell death, or genetic instability in 
proliferating cells. C). Cell cycle exit: The cell type specific replication program is compromised 
in a growing number of cells during aging, resulting in cellular senescence. Mature neurons lack a 








4.4. DNA BREAKS AND CANCER 
The regulation of cell cycle progression is of central importance to human health. The over-
proliferation of normal and particularly abnormal cell types can be detrimental to organ function. 
Our studies show that the pathway choice for the repair of a specific class of DNA damage: one-
ended double strand breaks is a critical determinant to cell proliferation and acts as a barrier to 
abnormal cell type transitions. Breaks at fragile sites of the genome and regions that are difficult 
to replicate curb cell growth by generating an antiproliferative signal, which involves p53, Rb and 
p21. We show that 53bp1 helps sustain this signal by counteracting homology-dependent DNA 
repair. Besides suppressing proliferation, p21 and Rb also have epigenetic effects [21], which play 
a role in limiting cell type transitions. Therefore, DNA damage during reprogramming acts 
upstream of both cell cycle progression and epigenetic changes.  
Similarly, increased replication stress in the first steps of tumorigenesis leads to oncogene-
induced senescence and constitutes a barrier to malignant transformation [175, 176]. Since DNA 
damage frequently occurs at fragile sites, the instability of these regions might act as a tumor 
suppressor independent of their role in encoding gene products. This barrier to transformation 
might be overcome if the site generating the signal is eroded through recurrent damage. Indeed, 
cancer cells often have deletions in late replicating regions [177]. The erosion may be accelerated 
by mutations in genes required for the integrity of late replicating regions, such as BRCA1 which 
would explain the early onset of BRCA1 mutant tumors. Thus, DNA damage in late replicating 
regions, specifically one-ended DSBs, is a cell type-specific growth and transformation 
suppressor, which may be exploited for therapeutic purposes.  
Current approaches to treat solid tumors already take advantage of this principle. Cytotoxic 
chemotherapies, which damage the DNA, mimic and amplify the signal emanating from late 
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replicating regions. However, while such treatments inhibit cell proliferation and promote 
apoptosis, they are not specific to genomic location and induce indiscriminate damage. To target 
exclusively the tumor in an effective manner, one may need to exploit the difference in replication 
patterns between healthy and transformed cells. Multiple groups have demonstrated that the 
temporal program of DNA replication differs between cell types, changes during differentiation or 
reprogramming and is altered in cancer [117, 146, 178]. However, the method portfolio to analyze 
DNA replication patterns genome-wide lags far behind the tools to study gene expression as 
biomedical research has traditionally focused on the products of the genome, rather than the 
genome itself. Emerging tools which can be used genome-wide are the optical mapping of DNA 
replication after incorporation of fluorescent nucleotides [179] and the detection of nucleotide 
analogs through pore sequencing [168, 180]. Nanopore sequencing is particularly suitable for 
mapping replication patterns as it can provide information on origin usage, replication fork 
direction, speed, pausing and stalling, all in a sequence-specific context. This information can be 
assembled into maps which detail replication traffic in healthy and malignant cells (Fig.27). Cancer 
cell specific replication problems can then be exploited for the development of targeted treatments, 
which selectively suppress the proliferation of the tumor, without affecting normal cells. The 
success of such efforts could fundamentally shift cancer care from treatment and management to 




Figure 27. Traffic analogy of DNA replication. 
A). Google maps of typical daily traffic in New York and Boston. In this analogy the two cities 
represent two different cell types. B). Some areas in each city incur traffic stalling, much like areas 
in the genome, which are difficult to replicate or are prone to breakage. These signals may be 
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